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ABSTRACT 
Many new drugs developed face oral delivery challenges and absorption due to poor 
biopharmaceutical properties. Formation of solid dispersions is a very widely applied 
technique for solubility enhancement of water insoluble drugs. In order to form stable 
solid dispersions it is important to select appropriate excipients that will maintain the 
drug in its amorphous form for an extended period of time. Selection of appropriate 
excipients is critical during the development of stable amorphous solid dispersions. The 
solubility parameter concept has been explored for theoretically identifying the 
excipients that will be suitable based on the structure of the active. In this work, the use 
of solubility parameter has been explored for strategic selection of excipients for a 
model drug ibuprofen. The predicted miscibility limits are verified with experimentally 
determined solubility limits. Dissolution experiments have been conducted to 
demonstrate the advantage of amorphous solid dispersions.  
This has been further extended by in depth thermal and chemical characterization of the 
ibuprofen and Eudragit® E PO system. A phase diagram is predicted based on the 
understanding of the relationship between temperature, ratio of ibuprofen and the Gibbs 
free energy. Room temperature miscibility of the two components is demonstrated using 
microscopic studies. The potential of ionic interactions is investigated using 
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spectroscopic techniques. Melt extruded formulations are evaluated for the physical 
state of ibuprofen and stability of the amorphous form. 
A complete Quality by Design study was performed for preparation of ibuprofen-
Eudragit® E PO extrudates. Risk assessment was performed using the fishbone 
diagram and Failure Mode Effect Analysis and the factors influencing this melt extrusion 
process were shortlisted and prioritized. The most critical factors were then assessed in 
a 30 run experimental design. Torque, Glass Transition temperature, Assay and 
Dissolution at 30 min were measured as responses and the results were statistically 
analyzed to predict a design space. Finally, mechanistic evaluation of Ketoconazole and 
Kollidon® VA 64 solid dispersions was performed using thermal techniques, dissolution, 
swelling and erosion studied.  
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CHAPTER 1                                                                                                        
INTRODUCTION 
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Increasing number of New Drug Entities (NDEs) filed have limited or no water solubility 
thus requiring specialized formulation techniques to increase the apparent solubility of 
the drug. It has been reported by several sources that about 40-50% NCEs fail due to 
their low water solubility or poor ‘drug like’ properties (1-6). Amidon et al proposed the 
Biopharmaceutical Classification System (BCS) which classifies drugs in four classes 
based on their aqueous solubility and permeability(7) (Table 1.1). Bergström et al have 
shown that drugs belonging to Class II can be completely absorbed upon oral 
administration(8). By using specific solubility enhancing formulation development 
techniques it is possible to increase the solubility and thus oral absorption of drugs 
belonging to BCS Class II.   
Table 1.1: Biopharmaceutical Classification System with examples 
Class Solubility Permeability Examples 
I High High Caffeine, Metoprolol, Quinidine 
II Low High Ibuprofen, Ketoconazole, Carbamazepine 
III High Low Atenolol, Metformin, Tetracycline 
IV Low Low Ritonavir, Acetazolamide, Oxcarbazepine 
Solid Dispersion Formulation 
Several approaches are available for improving the in vivo performance of poorly water 
soluble drugs such as amorphous solid dispersions(9), micronization(10),  
complexation(11), salt formation(12), and prodrugs(13). Preparation of amorphous solid 
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dispersions is gaining high interest as it can be easily adapted to almost any drug 
molecule and has a wide range of techniques available for manufacturing. The most 
common techniques for preparation of solid dispersions are hot melt extrusion(14), 
spray drying(15), co-grinding(16), co-precipitates(17) and freeze drying(18). Regardless 
of the method of manufacturing solid dispersions increase the apparent solubility of a 
drug by stabilizing its most high energy amorphous state. The polymer chains cause 
physical barrier and prevent (or delay) the crystallization and agglomeration of the drug 
molecules. A recent review of solid dispersions with 40 Active Pharmaceutical 
Ingredients(API) shows that 82% of the compounds exhibited increased bioavailability 
than the reference compound(19). 
Solid dispersions are mixtures of two or more ingredients that have the drug dispersed 
as amorphous ,crystalline or solubilized in a matrix of an inert material(20). Solid 
dispersions can broadly be classified as below 
1. Eutectic mixtures: The two components are completely miscible in the liquid state 
but partially miscible in the solid state; 
2. Solid solution: The two components are completely dissolved and form a single 
phase. The solid solutions are further classified as continuous and discontinuous 
depending on the range of miscibility of the drug and the carrier materials; 
3. Solid dispersions: Either amorphous or crystalline drug particles are dispersed 
throughout the carrier matrix; 
Although a lot of interest has been generated on the subject of solid dispersions there 
are not many marketed formulations. This can be attributed to some of the known 
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challenges for formulation development using the solid dispersion approach such as 
selection of manufacturing technique, reproducibility and scale-up of the manufacturing 
process, maintaining the amorphous state during shelf life of the formulation and in 
vitro/in vivo correlation. The carrier material is generally selected based on the chemical 
structure of the drug and the manufacturing process used for solid dispersion 
preparation. The carriers commonly selected for melt extrusion formulation development 
are discussed in further sections.  
Mechanisms of drug release  
The most important advantage of solid dispersion formulation is apparent solubility 
enhancement of water insoluble drug molecule. Reduction in particle size or changes to 
the physical properties of the drug molecule are regarded as the main reasons for 
increased solubility. Corrigan et al. showed correlation between dissolution rate of the 
drug and dissolution rate of the carrier by separately measuring both(21). In the carrier 
controlled drug release the dissolution rate of the drug is controlled by the dissolution of 
the carrier material. The rate of dissolution can be described with the Noyes-Whitney 
equation.  
!"!" = !!"!(!!!!)!!           (1.1) 
Where, 
!"!"  is the rate of dissolution, D is the diffusion coefficient, A is the surface area of the 
solid, Cs is concentration of solid in the diffusion layer, L is the thickness of diffusion 
layer.  
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The dissolution rate of the individual component (drug or carrier) will affect the 
composition of the diffusion layer which in turn dominates the drug release mechanism. 
Craig et al. summarize the three scenarios of where the drug dominates dissolving 
surface, carrier dominates dissolving surface and where both components dissolve in 
the same proportion(22). The knowledge of the dissolution mechanism will assist in 
prediction of the performance of a certain formulation. This could govern the selection of 
carrier materials at early stages of formulation development. 
Solid State Solubility 
During solid dispersion formulation development, often the drug is regarded as a solute 
and the polymer is considered as a solvent. The knowledge of solid state 
solubility/miscibility of drug and polymer is imperative for successfully preparing a stable 
formulation. Several theoretical as well as practical methods have been outlined for 
prediction of drug-polymer solid state solubility. The theoretical approach for 
solubility/miscibility determination is based on the solubility parameter approach. 
Solubility parameter (δ) is defined as the square root of cohesive energy density. 
References to this concept as early as 1916 are available however the symbol δ and 
the current definition was proposed in 1949 by Hildebrand. This concept was refined 
further by Fedors in 1974(23) exploring the additive properties of solubility parameter 
showcasing the group contribution theory.  
Although this solubility parameter is inclusive of energy contributions from the polar, 
dispersive and hydrogen bonding effects, this approach was further extended into a 3 
dimensional solubility parameters to separately account for energy contributions from 
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polar, dispersive and hydrogen bonding by Hansen(24). Further refinement of the 
concept of 3-D solubility parameters was made by Hoy(25) and Hoftyzer-Van 
Krevelen(26). It is generally considered that materials with close solubility parameter 
values are likely to have high miscibility. The solubility parameter when used in 
conjunction with the Flory-Chi parameter gives the ability to determine quantitative 
values for solid state solubility limits of drug in polymer. Several researchers have 
demonstrated the use of Flory-Chi parameters for estimation of solid state drug-polymer 
solubility (27, 28).  
The knowledge of the solid state solubility is beneficial for selecting drug loadings to 
yield stable solid dispersions and to stay below the saturation solubility. This approach 
reduces the time and resources required for development of formulation as it allows 
strategic shortlisting of the carrier polymers based on the molecular structure of the 
drug. Polymeric carriers that have a close structural similarity are likely to form 
thermodynamically stable molecular dispersions with enhanced apparent solubility of 
the drug molecule. 
Hot Melt Extrusion (HME) 
Hot Melt Extrusion (HME) has been explored as a tool to manufacture solid dispersions 
and solid solution for over two decades (14). HME has numerous applications within the 
pharmaceutical industry ranging from oral drug delivery applications such as solubility 
enhancement(29), controlled release(30), taste masking(31) and enteric protection(32) 
to manufacturing of implants for controlled parenteral drug delivery(33). There are 
mainly two basic types of extruders: single screw extruders and twin screw extruders. 
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Twin Screw Extruders (TSE) are most commonly used in the pharmaceutical industry 
and are available in a variety of manufacturing capacities(34). Most of the expertise 
associated with operation of TSE has been adopted from the plastics industry which has 
been continuously evolving for over 70 years(14, 35). Since its introduction in the 
pharmaceutical industry, the TSE have been modified to adapt to the pharmaceutical 
operation by using pharmaceutically compatible construction material like stainless 
steel, modified fittings and cleaning components, use of approved lubricants and gear 
oil as well as additional documentation for GMP qualification. 
HME is a thermal process where the drug along with other excipients is intimately mixed 
in the molten state. This technique has several advantages compared to traditional 
pharmaceutical compounding techniques. HME is a series of unit operations where 
feeding, mixing, melting, conveying and cooling takes place in a streamlined continuous 
operation(36). HME also offers the ability to tailor the final product based on the dosage 
form and intended application. One of the main advantages of HME is that the need of 
solvents is completely eliminated. The molten polymer acts are a binder, solubilizer and 
a vehicle during the manufacturing process. The intense heat and shear during the 
extrusion process melts and solubilizes the crystalline drug which on cooling gets 
entrapped in its most high energy amorphous state. Due to the nature of this process it 
is not suitable for heat sensitive drugs however the formulation can be adjusted to bring 
down the extrusion temperature. 
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Figure 1.1: Schematic representation of unit operations involved in a melt extrusion 
process 
Components of HME 
An average extruder is composed of a feeder/hoper, single or twin screws, barrel to 
hold the screws, heating elements, a die and a choice of downstream processing 
equipment (Figure 1.1). Additionally an extruder may have heat and pressure sensors, 
liquid/gas injection, additional feeding zones and Process Analytical Technology (PAT) 
tools for in line monitoring of the process. PAT tools like Near Infrared (NIR) (37) and 
Raman spectroscopy (38) have been used in conjunction with a TSE for in line 
quantification of the drug levels as well as monitoring drug-polymer interactions taking 
place inside the extruder  
Extrusion process can be categorized as either a ram extrusion or screw extrusion. A 
ram type extruder operates with positive displacement ram that generates high pressure 
to push the molten material through a die whereas screw extruder has rotating screws 
positioned inside a stationary barrel. The barrel itself has separate heating zones 
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designed to control the temperature of individual sections of the barrel. The barrel 
temperature can impact the physical characteristics of the formulation and is selected 
based on the thermal and chemical characterization of the ingredients (39).  
Most extruder screws have configurable screw elements having either mixing or 
conveying functions. Depending on the make and the model of the extruder, the 
conveying elements may have different flight lengths. The mixing elements are 
designed to generate intense shear and have maximum contribution to the overall 
torque levels experienced by the machine. Therefore, it is important to ensure that the 
temperature in the mixing region is sufficient to maintain appropriate viscosity of the 
extruding material. The direction of the screws can be either co-rotating or counter-
rotating. Co-rotating extruders may have an intermeshing, self-wiping design and are 
most commonly encountered in pharmaceutical industry as they can be run at high 
speeds while maintaining the product quality. The counter-rotating TSE generate a high 
amount of shear and works best in cases where intense mixing is desired(35). In 
process torque generation is dependent on the screw configuration, screw rotational 
direction and speed, melt viscosity of the material and extrusion temperature.  
The geometry of an extruder is defined in terms of its length to diameter ratio and typical 
extruder L/D ratios are in the range of 20 to 40:1.The length of the extruder along with 
the screw speed directly affects the residence time. Average residence time in the 
extruders can vary between 5 sec to 10 min depending on the operating conditions. 
Scale-up of extrusion process to an extruder with similar geometry is relatively easy(40). 
Theoretical values of the barrel temperature, screw speed and feed rate can be 
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calculated based on equations based on specific mechanical energy 
calculations(41).Scale-up of pharmaceutical melt extrusion process and its influence on 
the formulation characteristics have been investigated by Guns et al(41).  
Several choices of downstream processing equipment are available to use with the melt 
extrusion process. The molten material can either be pushed through a die to yield 
films, rods or pellets or it can be injection molded into any desired shape. Specially 
designed melt extrudates have been prepared for transmucosal, buccal, vaginal and 
transdermal drug delivery. Often, melt extrudates are milled to fine powder mixed with 
other excipients and either filled into capsules or compressed into tablets for 
conventional pharmaceutical solid dosage. 
Formulation Development for HME 
Selection of carrier material 
Along with appropriate processing conditions, selection of excipients is very important to 
success of a HME formulation and efficiency during manufacturing. Several 
pharmaceutically compatible carriers are available to use with the melt extrusion 
process. The main characteristics of a carrier material are: it should be inert, melt at a 
low temperature, stable over the shelf life of the product, cheap and easily available. 
Polymers from a wide range of chemical classes are available to select from. The 
selection of polymers for HME formulation may be based on the chemical structure of 
the drug as well as intended final application of the product. Low molecular amorphous 
polymers such as Polyvinyl pyrollidones (PVP) or polymethacrylates may be selected 
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for immediate release formulations whereas high molecular weight cellulosic polymers 
may offer good sustained release. Use of wax as a matrix former for controlled release 
of diclofenac is reported by Miyagawa et al(42). 
Polymethacrylate polymers are synthetically derived polymers based on 
dimethylamioethyl methacrylate, methacrylic acid and methacrylic acid esters. These 
polymers have glass transition temperatures ranging from 40 to 140°C depending the 
grade. Eudragit® E PO (Figure 1.2) is a cationic pcopolymer based on 
dimethylaminoethyl methacrylate chemistry and is soluble up to a pH 5.0. Eudragit® RS 
and RL (Figure 1.3) are pH independent polymers based on ethyl acrylate, methyl 
methacrylate methacrcrylic acid ester chemistry. Eudragit® L 100-55 (Figure 1.4) is an 
anionic polymer based on methacrylic acid and ethyl acrylate chemistry with dissolution 
above pH 5.5. Several applications of polymethacrylate polymers in HME are recorded 
for immediate release(31), controlled release(30), enteric protection(43) as well as taste 
masking(44).  
 
Figure 1.2: Molecular Structure of Eudragit® E PO 
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Figure 1.3: Structure of Eudragit® RL PO- x:y:z ! 1:2:0.2 and Eudragit® RS PO- x:y:z 
! 1:2:0.1 
 
Figure 1.4: Molecular Structure of Eudragit® L 100-55 
Polyethylene oxide (PEO) (Figure 1.5) polymers are semi-crystalline polymers 
synthesized by heterogeneous catalytic polymerization of ethylene oxide monomers. 
Depending on the molecular weight the melting temperature may range between 55 to 
75°C. Their applications as HME carrier materials have been investigated but additional 
antioxidants and crystallization inhibitors are needed for stabilization of the 
formulation(45).  
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Figure 1.5: Molecular structure of Polyethylene Oxide 
Cellulose based polymers are derived from naturally occurring cellulose in the plant 
cells. Several types of cellulose based polymers have been investigated for HME 
formulation development including Hydroxypropyl Cellulose (HPC), Hydroxypropyl 
Methyl Cellulose (HPMC) (Figure 1.6), Ethyl Cellulose (EC) and Hydroxypropyl Methyl 
Cellulose Acetate Succinate (HPMCAS. These polymers have been explored as HME 
carriers for immediate release(46), controlled release(47) and muco-adhesive film(48) 
formulations.  
 
Figure 1.6: Molecular Structure of Hydroxypropyl Methyl Cellulose 
PVP based polymers are synthetic polymers derived from vinyl pyrolidone and have 
been utilized as carriers for melt extrusion technology. They have been investigated as 
carriers for immediate release formulations (17, 49). Kollidon® VA 64 (Figure 1.7) and 
Soluplus® are some of the commonly used pharmaceutical polymers belonging to this 
class. Being a relatively new product, applications of Soluplus® for solubility 
enhancement are still being evaluated and currently it is not a part of any approved 
product. 
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Figure 1.7: Molecular structure of Kollidon® VA 64  
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Table 1.2: Commonly used carriers for HME formulations 
Chemical Name Trade Name Tg (°C) Tm (°C) 
Ammonio methacrylate copolymer Eudragit® RS/RL 63 - 68 -- 
Poly(dimethylaminoethylmethacrylate-
co-methacrylic esters) Eudragit
® E 45 - 48 -- 
Poly(methacrylic acid-co-methyl 
methacrylate) 1:2 Eudragit
® S/L 160 -- 
Cellulose Acetate Phthalate -- 165 192 
Poly(vinyl pyrrolidone) Kollidon® 90 - 156 -- 
Hydroxypropyl Methylcellulose 
Phthalate -- 137 150 
Polyvinyl pyrrolidone-co-vinyl acetate Kollidon® VA64 101 -- 
Polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft 
copolymer 
Soluplus® 70 -- 
Hydroxypropyl Methylcellulose (HPMC) Methocel
®, 
Benecel® 160 - 210 -- 
HPMC Acetate Succinate Aqoat-AS® ~ 120 -- 
Ethyl cellulose Ethocel
® 
Aqualon® EC 130 - 133 -- 
Hydroxypropyl Cellulose Klucel® ~130 -- 
Polyethylene Glycol Carbowax® -17 37- 63 
Polyethylene Oxide PolyyOx® WSR  -57 - 50 62 - 67 
Carnuba Wax --- 81 - 86 -- 
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Processing Aids 
As with any pharmaceutical process there may be a need for additional processing aids 
to increase the efficiency of the HME process. Plasticizers are generally required for 
high molecular weight, high melt viscosity polymers to bring the processing temperature 
down. Plasticizers are low molecular weight compounds with low Tg that reduce the 
overall softening temperature of melt. Depending on the hydrophilic or hydrophobic 
nature of the plasticizer it may have a positive or negative effect on the drug release 
rate. Plasticizers also assist in reducing the brittleness of the HME films thereby 
increasing the strength.  
In order for a material to work successfully as a plasticizer, it should be compatible with 
the drug and the carrier material used and be stable over the shelf life of the product. 
Citrate esters, fatty acid esters, sebacate esters, phthalate esters, glycol derivatives, 
mineral oil, castor oil and Vitamin E TPGS derivatives have been explored as 
plasticizers for HME process. In some instances where the Tg of the drug molecule is 
low, it can act as a plasticizer. Wu et al. reported the use of ibuprofen as a solid state 
plasticizer for extrudates prepared with Eudragit® RS PO(50). Formulation stability 
testing is recommended when working with plasticizers as due to the low molecular 
weight of the plasticizers there is a likelihood of the molecules leaching out over time 
thereby compromising the performance of the formulation. Additional processing aids 
such as anti-oxidants, preservatives, crystallization inhibitors, complexing agents, 
lubricants, anti-tacking agents may be necessary to cater specific needs of the drug 
molecule(36). 
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Analysis of Melt Extrudates 
Based on the thermo-mechanical properties of polymers, they are commonly classified 
as thermoplacstics, elastomers and thermosets. Owing to their linear nature, 
thermoplastics deform and flow when heat is supplied and will retain any shape as they 
cool. Most polymers selected for pharmaceutical melt extrusion belong to this category. 
Thermosets and elastomers due to their cross-linked nature retain the shape that they 
were manufactured for the first time forming a cross linked network. Due to these 
properties, thermosets and elastomers have limited pharmaceutical melt extrusion 
applications(26).  
Thermoplastic polymers can either be crystalline, amorphous or partially crystalline in 
nature. The crystallinity is associated with a long range three-dimensional order arising 
from the arrangement of the macromolecular chains. Amorphous polymers are hard and 
brittle at temperatures below their glass transition temperatures (Tg) whereas soft and 
pliable at higher temperatures. The glass transition temperature can be determined by 
either thermal or thermo-mechanical methods. Partially crystalline polymers like 
Polyethylene oxide may exhibit both a melting point (Tm ) as well as a Tg. Below the 
glass transition temperature, the movements of the chain segments vibrate around fixed 
positions. When the temperature increases, the amplitude of the vibrations increases 
and the rise in tension is translated to the intermolecular interactions. On further 
increase in the temperature, a fraction of the chain segments acquire enough energy to 
overcome these interactions. The glass transition temperature is the critical temperature 
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at which the molecular mobility can be detected. The glass transition temperature also 
affects the shelf stability of the melt extruded formulation.  
Melt extrusion experiments are performed at a temperature above the glass transition 
temperature of the polymeric carrier to ensure that the dry physical mixtures are 
sufficiently molten to allow for intimate mixing. Addition of drug, plasticizer and other 
processing aids may alter the range of the glass transition temperature. The final Tg of a 
formulation may be a result of additive effects from all the components and their 
proportions in the final mixture. The well-known fox equation has been demonstrated for 
prediction of Tg of a mixture based on the Tg of the individual components and their 
molar ratio in the mixture(51).  
!!! = ! !!!!,! + ! !!!!,!           (1.2) 
Where, !! and !! are weight fractions of components 1 and 2 respectively. 
During development of a solid dispersion formulation it is necessary to characterize the 
physical state of the drug, in vitro and in vivo performance as well as shelf stability of 
the prepared formulation. Several analytical techniques have been utilized for 
characterization of solid dispersion formulations as discussed below. 
1. Differential Scanning Calorimetry (DSC) 
DSC is a thermo-analytical technique which quantifies the amount of heat required to 
increase the temperature of a sample in comparison to a reference. The sample and 
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reference both are contained in identical aluminum pans that have the capacity for 
hermetic sealing. The samples are heated at a constant heating rate and the heat 
required to maintain constant temperature is recorded. Both high and low heating rates 
have been utilized for characterization of solid dispersions. The lower heating rates yield 
accurate melting point temperature measurement whereas the higher heating rates 
have been demonstrated as a tool to measure the solid state drug-polymer solubility(52, 
53). DSC is the most commonly used tool to determine the glass transition temperature 
of pure polymers as well as polymer mixtures(54). Although widely used for 
characterization of the physical state of the drug, DSC has several limitations. 
Conventional DSC falls short when analyzing materials with overlapping melting or 
transition events. Moreover, DSC cannot detect trace amount of crystalline phase 
therefore is often used in conjunction with XRPD analysis.  
2. X-Ray Powder Diffraction (XRPD) 
XRPD is a tool used for detection of crystalline phase in a sample utilizing the 
relationship between density of the material and absorption of X-rays. During XRPD 
measurement, the sample is subject to a beam of x-ray. The crystals in the samples 
diffract the x-ray in a characteristic pattern whereas an amorphous sample does not 
exhibit a diffraction pattern. XRPD is often utilized in conjunction with DSC to detect 
trace amount of crystalline phase. XRPD is an important tool during solid dispersion 
formulation development due to the accuracy of detecting phase change. A main 
disadvantage of using XRPD for melt extruded formulations is that the physical form of 
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the formulation is disturbed when milling in to a powder potentially changing the delicate 
thermodynamic balance.  
3. Thermogravimetric analysis (TGA) 
Due to the inherent nature of the melt extrusion process, thermal characterization is an 
important preformulation consideration. TGA analysis measures loss in weight of a 
preweighed sample as the temperature of the sample chamber is elevated at a constant 
rate(55). An additional application of TGA is to analyze the volatiles released from a 
sample upon heating.  
4. Fourier Transform Infrared Spectroscopy (FTIR) 
All chemicals exhibit characteristic IR spectra which have been used for identification, 
quantification and analysis of pure materials and mixtures. The FTIR spectra is 
generated from the chemical structure of a compound through the characteristic 
absorption bands associated with vibration of atoms in the infrared region. FTIR is often 
used to detect intermolecular interactions during melt extrusion processing. The shift in 
the absorption wavelength or appearance/ disappearance of characteristic peaks can 
allow investigators to identify potential molecular interactions(56).  
 Quality by Design 
Quality by Design (QbD) is an initiative by the Food and Drug Administration (FDA) to 
harmonize the process for new and generic drug applications. QbD is defined as “A 
systematic approach to development that begins with predefined objectives and 
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emphasizes product and process understanding and process control, based on sound 
science and quality risk management”(57). Pharmaceutical QbD requires a thorough 
understanding of the product and the process along with the knowledge of the 
relationship between the Critical Quality Attributes (CQAs) and the clinical performance 
of the product. The effect of individual process parameters on the final product’s CQAs 
is studied with the help of statistical Design of Experiments (DoE) through which an 
operational Design Space (DS) is established. As a result of this, a range of variability is 
defined for each variable under which the CQAs remain within the pre-established 
limits. Thus a controlled DS is generated for the process. Although adapting QbD 
methodology initially may be thought to be cumbersome, it eventually means less 
paperwork and resources when a change needs to be introduced in the manufacturing 
process. It will also reduce overall waste produced during manufacturing as well as 
allow efficient globalization for companies with manufacturing sites across the 
world(58),(59).  
QbD has been developed with an approach to improve the efficiency of the entire drug 
manufacturing and filing process. A typical QbD study has the following steps: 1. 
Establishment of Quality Target Product Profile, 2. Risk Assessment, 3. Screening and 
Optimization studies, 4. Generation of Design Space and 5.Control Strategy(57). A 
schematic for process development using implementation of QbD principles is 
presented in Figure 1.8. Application of QbD concept has been published for several 
pharmaceutical techniques such as fluid bed granulation(60, 61), spray drying(62, 63), 
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tablet compression (64, 65), liposomes(66, 67), sterile products(68) and gel 
manufacturing(69).  
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Figure 1.8: A schematic representation of process development using the QbD 
approach 
Establishment of Quality Target Product Profile (QTPP) 
The QTPP outlines the specifications of the final product that are essential to be built 
into the product during the developmental stage. This describes the profile of the 
product with respect to the physical appearance, assay, dosage strength, container 
enclosure system, pharmacokinetic characteristics as well as in vitro and in vivo 
performance. This profile acts as guidance throughout the product development phase. 
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Critical Quality Attributes (CQAs) 
A CQA is defined as “any physical, chemical, biological or microbiological property that 
should be within an appropriate range limit or distribution to ensure the desired product 
quality”(57). CQAs are measurable product attributes that can be derived from the 
QTPP or prior knowledge of the product. For a solid dosage form like tablets the CQAs 
can be tablet hardness, friability, disintegration time, assay, dissolution time. A CQA can 
also be an esthetic attribute of the product such as the physical appearance like color, 
size and shape of the logo, glossiness and so on. Additional CQAs from the 
manufacturing process such as curing time, temperature and feed rate may be 
considered for monitoring during the product development phase.  
Risk Assessment 
Out of the hundreds of factors potentially affect a pharmaceutical process, it is often 
difficult to select the most important factors. Risk assessment is a scientific tool for 
systematically shortlisting and prioritizing the factors that potentially have an impact on 
the CQAs. While there are several risk assessment tools available to use, the most 
commonly used techniques include construction of the fishbone (or Ishikawa) diagram 
and Failure Mode Effect Analysis (FMEA). Ishikawa diagrams were created by Kaoru 
Ishikawa to show the causes associated with a particular event(70). The causes are 
separated based on their source and each arm highlights causes associated with that 
particular source. The commonly addressed sources are people involved with the 
process, plant environment related factors, methods used for manufacturing, use of 
  
24 
specific machinery and equipment, source and nature of raw materials and analytical 
methods.  
The FMEA analysis is a tool to systematically analyze all the factors that potentially 
affect the product development. In a FMEA study, all possible factors are listed down as 
failure modes. The parameters listed in an FMEA study can be related to the process as 
well formulation. An interdisciplinary team of experts then grades each failure mode 
based on its occurrence, detectability and severity. Each failure mode is given an 
average score for each individual category and a product of these scores is further used 
to generate a Risk Priority Number (RPN). These failure modes are prioritized based on 
their RPN score and failures with the highest RPN are likely to cause a significant 
impact on the CQAs of the product. The shortlisted factors are then considered for a 
DoE based screening and optimization study.  
Design Space 
The DS is defined as “the multidimensional combination and interaction of input variable 
and process parameters that have been demonstrated to provide assurance of 
quality”(57). The parameters shortlisted in the risk assessment stage are further 
quantitatively analyzed using a DoE study. This also could be an opportunity for 
investigators to determine the levels of processing aids such plasticizer, glidants, 
antitacking agent at which optimum performance is achieved. Generally a full factorial or 
an Response Surface Model (RSM) is then employed to investigate the significance of 
each parameter in the study. The CQAs such as the dissolution rate, tablet hardness, 
disintegration time, assay and drug content uniformity are measured as responses. 
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Data analytical techniques like multi linear regression or partial least squares are then 
utilized for generating predictive models for measurement of individual responses. The 
analysis of the DoE study culminates into a DS that describes the relationship between 
process inputs (CPPs) and the measurable final product attributes (CQAs). A DS may 
be described in terms of the ranges of material attributes and process parameters or 
through complex mathematical relationships. A change of manufacturing conditions 
within the predefined design space does not require additional documentation and filing.  
Control Strategy 
After the initial processing ranges have been established and proven to yield the 
desired values of CQAs, a control strategy is designed to ensure that the product quality 
will be maintained. During development of control strategy, sources of variation are 
identified and their effect on the final product attributes are outlined. Control strategy 
may be designed to monitor the specifications of the incoming materials, unit operations 
during manufacturing, as well as real time testing. A control strategy can employ in line 
monitoring tools to monitor product attributes during manufacturing. This will facilitate in 
addressing potential failures before they occur.  
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CHAPTER 2                                                                                                                
OBJECTIVES 
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1. To evaluate application of solubility parameter theory for excipient 
selection for HME formulation development 
a. To theoretically predict the solubility parameters of ibuprofen and each of the 
carrier polymer selected based on the group contribution theory and the 
molecular structure. 
b. To measure the experimental solubility ranges using film casting and melt 
extrusion 
c. To demonstrate advantage of amorphous solid dispersions in vitro by 
performing dissolution experiments 
2. Thermal and chemical characterization of Ibuprofen-Eudragit® E PO solid 
dispersions prepared by HME 
a. Prediction of phase diagram based on the Flory-Chi theory outlining the 
temperature – composition relationship 
b. Evaluate and investigate molecular interactions using spectroscopic 
techniques 
c. Study the stability of the prepared melt extrudates at room temperature
3. Application of Quality by Design (QbD) approach for product development 
using HME  
a. Perform qualitative risk assessment by plotting the Fishbone diagram and 
Failure Mode Effect Analysis  
b. Perform quantitative risk assessment using a Placket-Burman experimental 
screening design 
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c. Analysis of the critical factors in a complete experimental design  
d. Prediction of the design space based on the analysis of the response values 
4. Evaluation of drug release mechanism of Ketoconazole – Kollidon® VA 64 
melt extrudates 
a. Preparation and analysis of melt extrudates  
b. Investigate the swelling and erosion behavior of the prepared extrudates 
c. Determine the drug release mechanism based on in vitro dissolution studies 
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CHAPTER 3                                                                                                         
POLYMER SCREENING APPROACHES FOR FORMULATION DEVELOPMENT 
USING MELT EXTRUSION 
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Introduction 
Solubility enhancement with the aid of solid dispersion formation has continued to be a 
topic of interest within the pharmaceutical industry and academia (18, 71). To become 
bioavailable, a drug should be soluble in gastrointestinal fluids and also be permeable 
through the cell membranes in the intestine. Solid dispersions offer the ability to freeze 
the drug molecule in its highly soluble amorphous form thus increasing the solubility and 
most likely the bioavailability of the drug (72).  
Pharmaceutical Hot Melt Extrusion (HME) is a thermal technique that involves mixing of 
the drug and polymeric excipients at temperatures above the Glass Transition (Tg) of 
the polymer thereby solubilizing the drug in the polymer(72). HME has gained significant 
momentum in recent years within the pharmaceutical industry for manufacturing solid 
solutions with enhanced solubility addressing the bioavailability issues of increasing 
number (~70%) of BCS II and IVNDAs (New Drug Applications) in the current R&D 
pipelines(3).  
Solid solutions are formed when there is significant structural similarity between the 
polymer and the drug. The drug-polymer miscibility has been estimated using 
theoretical (23, 73-76) approaches where the cohesive energy densities corresponding
each individual functional group in a molecule is accounted towards calculation of the 
total solubility parameter of the molecule. Extending this method, researchers have 
determined individual energy contribution from the polar, dispersive and hydrogen 
bonding forces (26). Such computationally calculated 3-D solubility parameters and their 
application in developing stable solid solution formation has been evaluated (76, 77). 
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Experimental approaches for solubility determination include melting point depression 
(27, 28), annealing(78), diffusion based(79), determination of drug-monomer 
solubility(80) and inverse gas chromatography(81). Knowledge of the drug-polymer 
miscibility values facilitates in selecting appropriate functional excipients to achieve the 
desired in vivo release profile. Depending on the choice of the excipients a wide range 
of dissolution profiles for immediate release as well as modified release can be 
accomplished using HME (39, 73, 82).  
Traditionally a more time consuming, trial and error based method is employed in which 
several excipients are screened in the laboratory. Efforts to expedite this process using 
automated robotic systems have been evaluated(82-84). These techniques demand 
specialized equipment, high amount of drug and therefore may not be always practical. 
Solubility prediction methods can be used as screening tools to shortlist the chemically 
most compatible polymeric carriers for a given drug component and thereby reduce the 
number of experimental trials. To increase chances of solubility enhancement using 
solid solution formation, it is important that the drug is maintained in its high energy 
amorphous form(18). Solid solution can be formed by ensuring that the concentration of 
the drug is below the saturation solubility (Cs) of the drug in given polymer. For this 
reason, it is important to know the solubility of the drug in the polymeric carrier in 
consideration.  
The objective of the present study was to evaluate the application of solubility 
parameters for selection of excipients for solid dispersion formulation development 
using melt extrusion. 3-D solubility parameter values for Ibuprofen and each polymer 
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selected for this study is predicted using Hoftyzer/Van Krevelen method that accounts 
for polar, dispersive and hydrogen bonding forces separately(26). Recently, after 
comparing theoretical and experimental solubility parameters, researchers have 
concluded that these conventional solubility parameter techniques are more accurate 
for common polymers(85). The difference in the solubility parameter gives an indication 
of miscibility of the two components. These ranges are then verified experimentally 
using film casting and melt extrusion experiments. A fourth type of force ie ionic 
interactions are studied separately experimentally in chapter 4. Ibuprofen a weakly 
acidic, non-steroidal anti-inflammatory drug categorized as BCS class II having a 
melting point (Tm) in the range of 75 to 77°C is used as a model drug for solubility 
determination. Eight pharmaceutical grade polymers with distinct chemistry were 
selected for the screening studies.  
Materials 
Ibuprofen (Albemarle, USA; BCS Class II) was used as model drug in this study. 
Plolymers EUDRAGIT® E PO, EUDRAGIT® L 100-55, EUDRAGIT® RL PO and 
EUDRAGIT® RS PO were obtained from Evonik Pharma Polymers (Evonik Corporation 
Piscataway, NJ, USA), HPMCAS-LF was obtained from Shin Etsu (Tokyo, Japan), 
Kollidon® VA 64 and Soluplus® were obtained from BASF specialty chemicals 
(Ludwigshafen,Germany). HPMC E5 was obtained from Dow Chemical (Midland, 
Michigan, USA). All polymers were used as received. Ibuprofen was sieved with a USP 
#35 screen to remove agglomerates. USP grade 190 proof ethanol purchased from 
Fisher Scientific was used as a solvent for film casting. 
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Methods 
Solubility Parameter Calculation 
The solubility parameter (δ) is a measure of cohesive energy density (Ecoh) per unit 
volume of a material. The Ecoh represents the total attractive forces within a condensed 
state of the material and can be defined as the amount of energy needed to separate 
the atoms/molecules to a distance where no interactions occur. Solubility parameters for 
ibuprofen and all polymers were calculated using the group contribution method outlined 
by Fedors which was later expanded by Hoftyzer-Krevelen (23, 26). The solubility 
parameters for polymers were calculated in two steps 1- calculation of solubility 
parameters of individual monomers and 2- calculation of solubility parameter of 
polymers based on proportional average of the monomers components. 
3D solubility parameters were originally defined by Hansen where the energy  
contribution from dispersion, polar and hydrogen bonding are separately calculated 
based on the molecular structure(24). Hansen defines the total solubility parameter as 
!!"# = !!! + !! + !!        (3.1) !!! = !!! + !!!! + !!!! !         (3.2) 
Where, subscript d stands for dispersive forces, p stands for polar forces and h stands 
for hydrogen bonding energy from self-association of the molecule. Contributions 
associated with dispersive, polar and hydrogen bonding forces were individually 
calculated using the following equations.  
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!! = ! !!"!              (3.3) 
!! = ! ∑!!"! !!             (3.4) 
!! = !!"!               (3.5) 
Based on the theory that ‘like dissolves like’, it is generally considered that materials 
with closely related solubility parameters are miscible. A drug is considered miscible in a 
polymer if the difference in their solubility parameter is less than 7 (δd- δp < 7) (73, 86). 
Film Casting 
Accurately weighed drug-polymer mixtures with the desired drug load (Total wt: 1.00 
gm) were dissolved in 30 mL ethanol using a magnetic stir station and allowed to 
equilibrate for 24 hrs. The resultant clear solution was transferred in a glass petri-dish 
and allowed to dry in a fume hood and tested for absence of solvent using a loss on 
drying apparatus. The prepared films were stored in air tight clear storage bags until 
further testing.  
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Figure 3.1: Structures of drug and polymers used in this study 
Melt Extrusion 
Binary mixtures of Ibuprofen with each polymer were prepared by weighing individual 
components and blending using a Turbula T2F shaker mixer (Glen Mills Inc.Clifton, NJ) 
for 10 min to ensure homogenous mixing. The mixtures were extruded using a 16mm 
co-rotating twin screw extruder (Leistritz Coporation, Allendale, NJ) complete with a 
bottom plunger feeding assembly and a 4mm round die. The four heating zones for this 
extruder equipment were set to 70, 140, 140, 140 °C however due to the plasticizing 
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effect of Ibuprofen(87) temperatures needed to be lowered for high drug load 
formulations. Extrusion screw rotation speed (150 rpm) and the feed rate (5cc/min) were 
maintained constant for all the batches. The extruded material was allowed to cool on a 
conveyor belt (Dorner, Hartland, WI) supplied with a jet of cool air and stored in airtight 
containers in a dark cabinet until further processing. All samples were milled using IKA 
A11 basic analysis mill and sieved through a USP #35 mesh screen. A small portion of 
the extrudate was flattened between two glass slides for microscopic analysis. The 
screws were pulled out and the barrel was cleaned after each set of formulations.  
All samples were milled using IKA A11 basic analysis mill and sieved through a 35 
mesh screen. Any material that did not pass through 60 mesh screen was transferred 
back in IKA A11 to be milled and sieved again. This process was repeated until all 
material passed through 60 mesh screen. The material that did not go through the sieve 
was stored separately and used for further analysis. The fines were eliminated by 
sieving through a screen with mesh number 200.  
Differential Scanning Calorimetry 
Differential scanning calorimetric analysis was performed on the milled extruded 
samples using a Pyris 6 DSC (PerkinElmer, Waltham, MI). 8 – 10 mg of the milled 
extrudate was weighed, crimped in an aluminum pan. The samples were heated to 
100°C at 20°C/min, cooled to 0°C and heated to 120°C at 20°/min under nitrogen purge 
of 20 ml/min..  The first heating eliminated the thermal history and moisture whereas the 
second heating facilitated in the determination of Tg. Samples with increasing ratio of 
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ibuprofen were analyzed and the ratio at which crystalline phase of ibuprofen could be 
detected was noted.  
Microscopy 
Optical analysis were performed on the film casted and extruded samples using an 
Olympus BX51 microscope (Center Valley, PA)c coupled with polarized filters to 
evaluate the drug’s physical state. A drug-polymer film is placed between two glass 
slides and observed with transmission mode under polarized light. The samples were 
stored at room temperature (25±2.5°C) and examined for recrystallized drug crystals 
periodically up to 1 year. 
Dissolution Testing 
The milled sample (equivalent to 200mg of ibuprofen) was filled in a size 00 clear 
capsule. Dissolution on the filled capsules was performed (n=3) using USP apparatus 2 
with a Varian VK 750 D dissolution equipment, at 37ºC and with a stir speed of 50 rpm 
in two media pH 1.2 and pH 6.8 separately. Dissolution samples were withdrawn using 
a Varian auto sampler connected to a spectrophotometer. A control sample, where 
200mg of pure drug was placed in a size00 clear capsule was used for comparison. The 
dissolution profiles obtained for ibuprofen samples were compared to that of marketed 
Ibuprofen soft gelatin capsules and IR tablets both with a dose of 200mg.  
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Results and Discussion 
Solubility Parameter Calculation 
The use of solubility parameters as tools to predict compatibility between drug/polymer 
systems have been demonstrated for many pharmaceutical systems(23, 73, 86, 88). 
The most common method used for calculation of solubility parameters is by using the 
group contribution theory developed by Hildebrand(89). This approach was further 
extended to separately calculate the contributions from hydrogen bonding, polar and 
dispersive forces(24, 26).  In this study, structure of model drug ibuprofen was 
defragmented into individual functional groups in order to determine the Hildebrand 
Solubility Parameter including the individual contributions corresponding to hydrogen 
bonding, polar and dispersive forces using the Hoftyzer-Van Krevelen method(26). 
Figure 3.2 shows defragmentation of the molecular structure of Ibuprofen and the 
groups that were used for solubility parameter calculation by group contribution method. 
Cohesive energies associated with each group were added to calculate the total 
cohesive energy Ecoh for the entire molecule. The solubility parameter was then 
calculated based on the equation 3.2. Similar method was applied to calculate the 
solubility parameters of monomers. The solubility parameter of the polymer δpoly was 
then calculated by taking proportional average of individual monomers.  
The cohesive energy is the summation of all the molecular interactions including 
dispersive, polar, hydrogen bonding as well as the ionic interactions. Compounds with 
similar cohesive energies are likely to be miscible with each other. If the difference in 
solubility parameters of the drug and that of the polymer is less than 7 (δp-δd) then the 
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two are generally considered to be miscible(86). Several researchers have explored use 
of solubility parameters approach to determine drug/polymer miscibility and solubility 
(53, 73, 74, 78). The calculated solubility parameter and miscibility estimations in terms 
of difference in solubility parameter for ibuprofen and each polymer considered in this 
study is given in Table 3.1. The lower values of δp-δd indicate higher miscibility. In the 
case of ibuprofen, the higher miscibibility is expected for Eudragit® E PO, Eudragit® L 
100-55, Eudragit® RS PO, Eudragit® RL PO, Kollidon® VA 64 and Soluplus® whereas 
borderline miscibility is expected in polymers HMPCAS-LF and HPMC.  
Bagley et al observed the similarities between δd and δp and derived the following 
expression(90)  
!! != ! !!!!+!!!!!           (3.6)!
A plot of δv and δh can outline the compatible solvents for a certain drug molecule based 
on the chemical structure of the drug and the polymers. Such a diagram for ibuprofen 
and the polymers considered in this study is shown in Figure 3.3. The circle represents 
an approximate delimited region of solubility for ibuprofen. It can be seen that the 
predictions based on the difference in solubility parameter are further confirmed using 
the δv- δh plot. These estimations are further verified using experimental techniques.  
  
40 
 
Figure 3.2: Molecular Defragmentation of Ibuprofen Structure 
Table 3.1 Difference in solubility parameter of the drug and polymer 
 Solubility Parameter (δ) |δp-δd| 
Ibuprofen 18.98 NA 
Eudragit® E PO 21.40 2.42 
Eudragit® L 100-55 19.77 0.79 
Eudragit® RS PO 21.61 2.63 
Eudragit® RL PO 21.53 2.55 
Kollidon® VA 64 26.12 7.14 
Soluplus®  22.97 3.99 
HPMC 37.51 18.53 
HPMCAS-LF 36.23 17.25 
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Experimental Solubility 
To further test the reliability of this predicted miscibility approach, the ranges of solubility 
were determined experimentally using ethanol casting and melt extrusion using various 
drug loads. Spray drying and melt extrusion are two commonly used techniques for 
manufacturing of solid dispersions. Due to the solvent interactions involved, results 
obtained from ethanol casting are likely to be comparable to solid dispersion 
manufacturing techniques like spray drying where the effects of solvents need to be 
taken into consideration. Melt extrusion experiments were conducted for each polymeric 
excipient with varying ibuprofen concentrations. The extrudates were analyzed using 
DSC and microscopy to identify recrystallization. Table 3.2 compares the predicted and 
the experimental solubilities of ibuprofen in select pharmaceutical polymers.  
Extrudate Analysis 
DSC studies were conducted for characterization of the physical state of the drug. The 
change in the enthalpy due to melting of the crystalline drug results in a characteristic 
melting event in the DSC thermogram. In absence of a crystalline drug no such event 
was observed. Samples with increasing ibuprofen loading were screened and compared 
with a thermogram of a blank polymer sample. The concentration at which a melting 
event could be seen was regarded as the saturation solubility of the drug in the polymer 
solvent. DSC scans for melt extrudates of ibuprofen with each polymer are presented in 
Figure 3.12. The saturation solubility values obtained from the DSC studies were further 
confirmed with microscopic examination of the films.  
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Figure 3.3: δv – δh diagram showing solubility of Ibuprofen in selected polymers  
 
Figure 3.4: DSC thermograms of Ibuprofen- Eudragit®  E PO melt extrudates 
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Figure 3.5: DSC thermograms of Ibuprofen- Eudragit® L 100-55 melt extrudates 
 
Figure 3.6: DSC thermograms of Ibuprofen- Eudragit® RS PO melt extrudates  
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Figure 3.7: DSC thermograms of Ibuprofen- Eudragit® RL PO melt extrudates  
 
Figure 3.8: DSC thermograms of Ibuprofen- HPMCAS-LF melt extrudates  
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Figure 3.9: DSC thermograms of Ibuprofen- HPMC melt extrudates 
 
Figure 3.10: DSC thermograms of Ibuprofen- Soluplus® melt extrudates 
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Figure 3.11: DSC thermograms of Ibuprofen- Kollidon® VA 64 melt extrudates 
Polarized light is reflected by crystals present in the study sample thus making detection 
of crystals easy. The optical microscopic analysis performed on the samples allowed 
detection of recrystallization in the solid solutions prepared by film casting and HME. 
Microscopic analysis was performed to verify the results of the DSC scanning. In certain 
instances when the percent crystallinity is low, the DSC thermograms may not detect 
enthalpy associated with crystallization. An amorphous solid solution appears black 
under polarized light (Figure 3.12) and the crystals appear luminescent making them 
easy to identify (Figure 3.12 (b)). From the DSC and microscopic results, a range of the 
solubility/miscibility of drug in each of the polymeric matrix was obtained. These 
experimental solubility ranges for all the samples is given in Table 3.2 in comparison to 
the predicted miscibility ranges based on difference in the calculated solubility 
parameter. 
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(a)                                                                    (b)                  
Figure 3.12: Ibuprofen -Eudragit® E PO melt extrudate under polarized light (a) 55% 
ibuprofen (b) 70% ibuprofen 
Table 3.2: Comparison between predicted and experimental solubility values 
Polymer Predicted miscibility Film Casting HME 
Eudragit® E PO High 65 65 
Eudragit® L100-55 High 7.5 35 
Eudragit® RL PO High 27.5 25 
Eudragit® RS PO High 27.5 25 
HPMCAS-LF Low 25 25 
HPMC-E5 Low 12.5 15 
Kollidon® 64 High 55 55 
Soluplus® High 25 45 
Evaluation of Solid Dispersions prepared by HME 
The prepared melt extrudates were evaluated for solubility enhancement using in vitro 
dissolution apparatus. For each polymer, formulations with ibuprofen concentration 
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below the maximum solubility were selected for dissolution testing therefore the drug 
was in the amorphous form in all the formulations. Being a weak acid, Ibuprofen shows 
pH dependent solubility. Practically no drug release was observed in the pH 1.2 media 
except for the Eudragit® E PO formulation, where the release 3 folds higher when 
compared to the pure ibuprofen as well as the standard ibuprofen tablet and soft gel 
formulation (Figure 3.13). This increase in dissolution can be attributed to the formation 
of ionic interactions between the anionic drug and the cationic polymer and is further 
investigated in chapter 4 of this document. It has been reported by Jamali et al. that 
increase in the dissolution at the gastric pH overall increases the drug absorption across 
the gastro-intestinal tract(91).As soon as the pH of the media is switched to 6.8 the 
ibuprofen control releases 90% within the first 60 minutes (Figure 3.14). At this pH, the 
influence of the properties of the carrier polymer on the release profile is evident. 
Release from the melt extruded formulations appears to be slower due to the fact that 
additional time is required for polymer dissolution and matrix erosion.  
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Figure 3.13: In vitro dissolution of prepared ibuprofen melt extrudates with individual 
polymers at a concentration below the maximum solubility in pH 1.2 
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Figure 3.14: In vitro dissolution of prepared ibuprofen melt extrudates with individual 
polymers at a concentration below the maximum solubility in pH 6.8 
Conclusion 
In summary, this study compares the predicted miscibility ranges based on the 
molecular structure with the actual experimental values obtained from the film casting 
and HME experiments. Theoretical solubility prediction has several limitations due to the 
fact that it does not consider the steric and isomeric hindrances as well as interactions 
introduced due to the processing factors like heat, torque or solvent related interactions. 
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In spite of these limitations, this method provides a reasonable alternative to expensive 
and time consuming experimental screening and provides a starting point for short 
listing of suitable excipients. The predicted values were in accordance with the 
experimentally determined ranges of solubility. The solubility parameter concept does 
not account for ionic interactions between the drug and the polymer that may explain 
the discrepancy in experimental and predicted solubility levels for ionic polymers like 
Eudragit® E PO. The solubility of drug in polymer ranking order is supported with 
experimental data. 
Solubility parameters can aid in selection and shortlisting of excipients for a HME 
formulation and can generate miscibility profiles for an API with commonly available 
pharmaceutical polymers if the chemical structures are known. In this study, the use of 
solubility parameter concept in selection of excipients for a model drug ibuprofen was 
demonstrated. Such methods will reduce the time and resources required during the 
initial stages of product development.  This approach for polymer screening is intended 
to serve as a starting point for experimental trials followed by further in depth analysis 
and may also serve as a guide in selection of specific functional excipients for enteric, 
sustained and modified release applications. Knowledge of solid state solubility will 
facilitate in determining percent drug loading while design and development of solid 
dispersion formulation for solubility enhancement.  
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CHAPTER 4                                                                                                       
THERMAL AND CHEMICAL CHARACTERIZATION OF SOLID DISPERSIONS 
PREPARED WITH EUDRAGIT® E PO AND IBUPROFEN 
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Introduction 
Solubility enhancement of poorly water soluble BCS Class II and IV drugs has been one 
of the most important challenges as about 40-70% of new drug molecules are poorly 
water soluble(3).Solid dispersions offer the ability to freeze a drug molecule in its most 
high energy amorphous form increasing the apparent solubility (18, 46, 71, 92). 
Methods for manufacturing solid dispersions include freeze drying, spray drying, solvent 
film casting, self-emulsifying lipid formulations and hot melt extrusion (HME). Formation 
of a solid facilitates stabilization of the API in its high energy amorphous state for an 
extended period of time. A lot of focus is given to characterization of physical form of the 
drug in solid dispersions. In some instances however, amorphization of the drug may 
not be the sole contributing factor for solubility enhancement. Systems containing ionic 
complex of a drug with an excipient offer the ability to further increase the apparent 
solubility of a poorly water soluble drug (93, 94).  
Solubility of a drug in a polymer is usually very low therefore it is difficult to meet the 
conventional dose requirements with solid dispersion formulations. For this reason, 
most solid dispersions potentially are developed as supersaturated systems. In some 
cases additional stabilizers and solubilizers are necessary to assist in solubility 
enhancement. Selection of the appropriate polymeric excipient is critical to have the 
highest concentration of drug solubilized. Strong drug-polymer interactions are 
favorable due to their ability to produce stable, higher drug load solid dispersions. 
Strategic selection of excipients to form ionic interactions offers the ability increase the 
apparent solubility of the drug. In the previous chapter polymers of varying chemistries 
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were investigated for compatibility with the model drug ibuprofen. In this chapter further 
thermal and chemical characterization of binary solid dispersions prepared using 
Ibuprofen and Eudragit® E PO is performed.  
For formulation optimization using HME, it is essential to understand the important 
physicochemical properties such as the Glass Transition (Tg), melt viscosity, solid-state 
saturation solubility and interactions between the drug and the excipients incorporated. 
A phase diagram describing the effect of temperature and the ratio of ibuprofen on the 
physical state of the drug is investigated in this study. Since maintaining stable 
amorphous state of the drug via solid dispersion formulation is critical for solubility 
enhancement knowledge of the phase diagram will provide vital information required for 
developing stable solid dispersions.  
For an immediate release formulation, increased solubility of a drug in the gastric pH is 
advantageous as the dissolution process starts as soon as the drug is orally 
administered. This also ensures that the drug is in the solubilized form and ready for 
absorption on entering the intestine (91). Eudragit® E PO is a good solvent for many 
classes of drug molecules mainly anionic and neutral drug. Due to the low Tg of this 
polymer processing using solid dispersion manufacturing techniques like HME and 
spray drying can get challenging when working with a drug molecule with a low Tg. For 
this reason, thorough understanding of thermal and chemical properties of this excipient 
is essential in order to determine experimental conditions within which stable processing 
can be achieved. In detail study on the effect of processing parameters on quality of the 
final product is presented in chapter 5. 
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In the present study, thermal and chemical characterization of ibuprofen and Eudragit® 
E PO binary mixtures have been performed using thermal and spectroscopic methods. 
Eudragit® E PO, is an amorphous polymer with a Tg at about 45°C is insoluble in 
aqueous systems above pH 5.5 making it an excellent carrier for taste masking bitter 
drugs. Ibuprofen a low melting (75-77°C), anionic drug is selected as a model drug as 
model drug. Ionic interactions between Eudragit® E PO and acidic drugs have been 
investigated by solubility measurement and FTIR spectroscopy.  
Materials 
Ibuprofen was generously donated by Albermarle. Eudragit® EPO was obtained from 
Evonik (Piscataway, NJ). Chloroacetic acid, acetonitrile and ammonium hydroxide were 
purchased from fisher Scientific (Pittsburgh, PA) 
Methods 
Phase Diagram 
Phase diagram was calculated based on the melting point depression method and the 
Flory-Huggins theory(95). According to the Flory-Huggins theory, a temperature 
composition phase diagram can be constructed for a given drug-polymer system if the 
Flory chi parameter is known for a given temperature range. Melting point depression 
method has been used previously to predict the value of ! by Marsac et al based on the 
equation 4.1. 
!!! !− ! !!!! = !− !!" ! !"! + ! !− !! !−! + !! !−! !      ( 4.1) 
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Where T! is the melting point of the drug polymer mixture, T!!  is the melting point of the 
pure drug, ! is the volume fraction of the drug, m is a constant derived from the ratio of 
the volume of a polymer to that of the drug molecule and ! is the Flory- Huggins 
interaction parameter(27, 53). It was recently noted that the Flori-Huggins interaction 
parameter is temperature dependent(96, 97) .A relationship between ! and temperature 
can be expressed based on the equation 4.2. 
! = !+ !!!             (4.2)  
Where A is a constant from non-combinatorial entropic contribution to ! and B/T is a 
constant coming from the enthalpic contribution(98). 
The free energy of mixing can be written in terms of the Flory-Huggins parameter as 
shown in equation 4.3 
!" = !"! !"#!+ !!!!! !!" !−! + !!! (!−!)      (4.3) 
The crystalline phase boundary is calculated using predicted values of Tm based on the 
equations4.1 and 4.2.  In order to calculate the spinoidal curve for phase separation, Ts 
is calculated from the second derivative of equation 4.3 equated to zero as shown in 
equation 4.4.  
!! + !! !(!!!) − !" = !        ( 4.4) 
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Melt Extrusion 
Powder blends of Ibuprofen with Eudragit® E PO were prepared by mixing accurately 
weighed powder components using a Turbula T2F shaker mixer (Glen Mills Inc.Clifton, 
NJ) for 10 min. Melt extrusion was performed in 40 gm batch sizes using a co-rotating 
twin screw extruder (Leistritz Nano 16, American Leistritz Corporation, Somerville, NJ). 
Screw rotation speed (150 rpm) and feed rate (5cc/min) using the bottom plunger feeder 
was maintained constant for the entire set of experiment. Due to the plasticizing effect 
of ibuprofen, extrusion temperature was adjusted based on the Tg of the mixture and 
ranged from 80 to 140°C. The resulting extrudates were stored at room temperature in 
air tight containers until further analysis.  
Thermal Analysis 
Differential Scanning Calorimetric (DSC) analysis was performed on the drug polymer 
solid dispersions using a Pyris 6 DSC (PerkinElmer, Waltham, MI). 8 – 10 mg of the 
milled extrudate was weighed, crimped in an aluminum pan and subjected to a heat-
cool-heat cycle.  
Measurement of glass transition: Samples were heated from 0 to 100°C at the rate of 
10°C/min, cooled to -50°C at 40°C/min and reheated up to 120°C at heating rate of 
10°C/min under nitrogen purge of 20 ml/min. The first heating eliminated the deviations 
caused from the thermal history and moisture whereas the second heating facilitated in 
the determination of Tg. DSC scans for the pure ibuprofen and Eudragit® E PO was 
measured as controls.  
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Melting point depression measurement: Binary mixtures of ibuprofen and Eudragit® 
E PO containing 65, 70, 75, 80, 85, 90 and 95% ibuprofen were dissolved in 5mL 
ethanol and stirred until a homogenous solution is obtained. This solution was poured 
into a petri dish (35mm) and allowed to dry for 3 days under a hood. The resulting films 
were analyzed in a DSC first by cooling to -50°C, heating from -50°C to 40°C at 
10°C/min followed by heating from 40°C to 90°C at 1°C/min to measure the melting 
point. The melting point was calculated at the falling edge of the melting endotherm. 
Optical Microscropy 
Optical analysis were performed on the extruded samples using an Olympus BX51 
microscope (Center Valley, PA) coupled with polarized filters to evaluate the drug’s 
physical state. A 1:1 physical mixture of ibuprofen and Eudragit®  E PO was observed 
under a microscope for 12 days.The melt extruded samples were examined for 
recrystallized ibuprofen periodically over a span of 1 year.  
XRPD 
X-ray diffraction (XRD) was investigated using D4 Endeavor (Bruker 
Corporation,Billerica, MA, USA). XRPD measurements assisted in physically 
determining the presence of crystalline phase. This analysis verified the results of the 
DSC measurements as well as phase diagram prediction.  
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FTIR 
The ATR-FTIR was used to identify the ionic interactions between the drug and the 
polymer. The IR spectra of the samples were collected by placing the samples in 
powder or film form on a single-reflection diamond ATR (Attenuated Total Reflectance) 
accessory. 32 scans were obtained for each sample at the resolution of 2 cm-1. 
Solubility Measurement  
Increasing amount of Eudragit® E PO was added to super saturated solutions of 
ibuprofen in 10 mL 0.1N HCl and allowed to equilibrate overnight. Resulting solutions 
were filtered and the supernatant solution was analyzed using a HPLC system equipped 
with a photodiode array detector at 254nm (Waters Corporation, Milford, MA) along with 
a C18 column (Waters Xbridge, 3.5 micron, 4.6x 150 mm). A mobile phase consisting of 
1% chloroacetic acid buffer solution adjusted to pH 3.0 with ammonium hydroxide and 
acetonitrile in the ratio 20:80 was used at a flow rate of 0.8 mL/min. All the standards 
and assay samples were prepared in acetonitrile. To test the effect of change in pH on 
the saturation solubility of ibuprofen supersaturated solutions of ibuprofen were 
prepared using pH 4.5 and 6.8 buffer solutions. pH values for all the solubility samples 
along with 300mg and 500mg Eudragit®  E PO dissolved in 10 mL 0.1N HCl as controls 
were recorded. 
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Results and Discussion 
1. Thermal Characterization: Phase Diagram 
The DSC thermograms measured for various ratios of ibuprofen and Eudragit® E PO 
are shown in Figure 4.1. The solvent casting may increase the amount of amorphous 
drug due to the presence of polymer chains resulting in melting point depression. This 
also provides an evidence of intimate mixing between the drug and the polymer. The 
crystalline ibuprofen shows a sharp melting peak at 78.08°C and this further decreases 
as the concentration of Eudragit® E PO in the system increase. The melting point 
depression data was used to calculate the Flory Chi parameter for the ibuprofen –
Eudragit® E PO system based on equation 4.1. Table 4.1 shows the values of the 
physical properties that were used in calculation of the constant m.  
Table 4.1: Molecular Weight and Density of Ibuprofen and Eudragit® E PO 
 Molecular Weight Density (gm/ml) 
Ibuprofen 206.28 1.03 
Eudragit EPO 47000 0.811 
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Figure 4.1: DSC thermograms of Ibuprofen and solvent casted solid dispersions of 
Ibuprofen and Eudragit® E PO obtained at a scanning rate of 1°C/min 
 
Figure 4.2: Flory-Huggins interaction plot based on equation 4.1  
  
62 
A Flory-Huggins interaction plot based on the equation 4.1 is shown in Figure 4.2. The 
slope of the straight line is the value of the Flory Chi interaction parameter and for the 
current study the calculated Chi is -1.52. Negative Chi values are associated with higher 
degrees of miscibility therefore the components are predicted to have high compatibility 
resulting in stable solid dispersions. Measurements of Flory Chi parameter based on the 
melting point depression data has been performed for similar pharmaceutical systems 
(27, 28) 
 
Figure 4.3: A plot showing the relationship between the interaction parameter and 
temperature. 
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The melting point data can be used to extrapolate the value of Chi at different 
temperatures using equation 4.1. There exists an inverse relationship between Flory Chi 
and Temperature as shown in equation 4.2. The predicted interaction parameter values 
are plotted against 1/T to get an equation of the straight line based on equation 4.2, ! 
=5794/T-18.61. The values of A and B are further used to predict the phase boundaries. 
 
Figure 4.4: A plot showing Gibbs free energy changes with respect to temperature for 
Ibuprofen-Eudragit® E PO system 
The phase diagram predictions are based on the Gibbs Free energy calculated using 
the equation 4. 3. Phase separation is dependent on the difference of the Gibbs free 
energy between the mixed and unmixed states which is also referred to as ΔGmix(74). A 
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plot of ΔG/RT against the ratio of ibuprofen is presented in Figure 4.4. It can be seen 
that at temperatures above 25°C the ΔG is negative across all ratios of ibuprofen 
indicating that at this temperature the system is miscible at all concentrations. At 20°C 
the ΔG starts getting positive at an ibuprofen concentration of 75%w/w whereas at 10°C 
the ΔG starts becoming positive at a concentration of 25%w/w. Overall, miscibility 
reduces as the temperature drops. 
The relationship between the Gibbs free energy, temperature and volume fraction of the 
drug can be used to calculate the temperature at which phase change occurs for each 
volume fraction of the drug. The spinoidal curve is calculated by equating the second 
derivative of the Gibbs free energy to zero as presented in equation 4.4. This is the 
boundary that outlines the miscibility limits of the two systems where the drug is present 
in a metastable state. In this region, the system may be sensitive to fluctuations in the 
levels of temperature or composition and may cause nucleation and recrystallization 
with larger fluctuations. The predicted melting points outline the region between 
crystalline and amorphous ibuprofen.  
Tg for the mixtures were measured experimentally using DSC measurements. The first 
heating eliminated prior thermal history of the material as well as the moisture present in 
the sample whereas the second heating cycle allowed determination of Tg. For samples 
in which ibuprofen exists in two phases (crystalline and amorphous), a melting event 
around 70°C can be detected in the first heating cycle. A change in the Tg can be 
witnessed in the DSC thermograms as seen in Figure 4.5.  
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Figure 4.5: Tg determination for binary mixtures of Ibuprofen and Eudragit® E PO  
 
Figure 4.6: Predicted phase diagram for Ibuprofen and Eudragit® E PO system 
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A phase diagram is a graphical representation of phase boundaries in relation to the 
temperature and composition. A predicted phase diagram for ibuprofen –Eudragit® E 
PO system is presented in Figure 4.6. Based on the phase diagram, it can be seen that 
the mixture of two components exists in a miscible state at room temperature.  
Room temperature Miscibility Study 
To further explore the fact that that the Tg of high ibuprofen containing (<50%) samples 
is well below the room temperature (Figure 4.7) a miscibility study was conducted. A 1:1 
mixture of powder Eudragit® E PO and Ibuprofen was observed under an optical 
microscope (100X) for a period of 12 days. Particles of Eudragit® E PO coated the 
ibuprofen crystals as seen on day 1 due to their significantly lower particle size and 
strong adhesive forces. The strong interactions between the two components slowly 
start dissolution process and the size of the ibuprofen crystal appears to be reduced as 
the days progress as seen in Figure 4.7 (a – h). Towards the end of 12 days the distinct 
shape of ibuprofen crystal disappeared indicating that the ibuprofen was most likely 
converted to its amorphous form due to solubilization in the polymer solvent. This is 
further confirmed by observation of crystals under polarized light. The outlines for 
ibuprofen crystals are clearly visible on day 5 whereas the day 10 image shows no 
reflectance under polarized light indicating absence of crystals as seen in Figure 4.5. 
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Figure 4.7: Room Temperature Miscibility 
   
   (a) Day 1:      (b) Day 2 
   (c) Day 5     (d) Day 6     
    (e) Day 7     (f) Day 8 
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(g) Day 9       (h) Day 12 
 
 
 
 
 
 
   Under polarized light (i) Day 5     (j) Day 10 
2. Chemical Characterization 
The mutual miscibility of ibuprofen and Eudragit® E PO can be attributed to their 
chemical structure. Chemical characterization was carried out to test for presence of 
intermolecular interactions.  
FTIR 
The room temperature miscibility study visibly shows the solubilization process between 
the two components. FTIR scans on the melt extruded samples further verify the 
formation of molecular interactions. The FTIR spectra show a broad peak at 1567cm-1 
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(absent in the physical mixture) which may be associated with the bending N-H bond 
vibrations. This could be an indication of interaction between the carboxylic acid group 
of the ibuprofen molecule and the dimethylaminoethyl group of the EUDRAGIT® E PO. 
Schematic representation of complex formation is presented in Figure 4.8. 
 
Figure 4.8: FTIR spectra of Ibuprofen-EUDRAGIT®  E PO samples  (--) Ibuprofen, (--), 
Eudragit®  E PO, (--) Physical Mixture, and (--) Melt Extrudates with 50% Ibuprofen 
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Figure 4.9: Schematic of Ionic Interactions 
XRPD 
The XRD scans are essential to determine the physical state of the drug. In this study 
XRD analysis was performed to verify the results obtained from DSC. It can be seen in 
Figure 4.10 that the crystalline ibuprofen shows distinctive peaks at 6, 16.5, 18, 20 and 
22.5 degrees owing to the specific arrangement of the atoms. Melt extrudates with 30, 
50 and 70% ibuprofen have been analyzed to detect the presence of crystalline phase. 
Crystalline phase could not be detected in the extrudates with 30 and 50% ibuprofen. 
However, the melt extruded formulation with 70% ibuprofen shows the same 
characteristic peaks as that of the pure ibuprofen indicating presence of crystalline 
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phase. These findings further support the results of the thermal and microscopic 
assessment.  
 
Figure 4.10: XRPD scans of Ibuprofen and Eudragit® E PO melt extrudates 
Increase in apparent solubility  
Ibuprofen has a pH dependent solubility with a pKa=4.85 and is poorly soluble at acidic 
gastric pH. For an immediate release formulation it is advantageous if the drug 
dissolution process is triggered as soon as the formulation is administered orally so that 
the drug is ready to be absorbed upon entering the intestine(91, 99). Solubility studies 
have shown that the saturation solubility of ibuprofen at pH 1.2 increases with increase 
Ibuprofen 
Ibuprofen-Eudragit E PO Formulations - XRPD
70% Ibuprofen - Eudragit E PO (extrudate) - File: XR130089.raw - Start: 4.000 ° - End: 39.997 ° - Step: 0.018 ° - Step time: 100.2 s - Generator kV: 40 kV - Generator mA: 40 mA - Creation: 8/20/2013 5:02:28 PM
50% Ibuprofen - Eudragit E PO (extrudate) - File: XR130088.raw - Start: 4.000 ° - End: 39.997 ° - Step: 0.018 ° - Step time: 100.2 s - Generator kV: 40 kV - Generator mA: 40 mA - Creation: 8/20/2013 4:51:02 PM
30% Ibuprofen - Eudragit E PO (extrudate) - File: XR130087.raw - Start: 4.000 ° - End: 39.997 ° - Step: 0.018 ° - Step time: 100.2 s - Generator kV: 40 kV - Generator mA: 40 mA - Creation: 8/20/2013 4:39:35 PM
Eudragit E PO Control - File: XR130086.raw - Start: 4.000 ° - End: 39.997 ° - Step: 0.018 ° - Step time: 100.2 s - Generator kV: 40 kV - Generator mA: 40 mA - Creation: 8/20/2013 4:28:08 PM
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in the concentration of the cationic polymer (Figure 4.11). This increase could be due to 
the molecular interactions between the carboxylic group of ibuprofen and 
dimethylaminoethyl group of the EUDRAGIT® E PO. This was further tested by 
measuring the change in pH of the solubility measurement samples with the addition of 
the cationic polymer. The pH of the saturated solution of ibuprofen with the maximum 
concentration of (500mg in 10 ml) of Eudragit®  E PO tested was 4.5 whereas that of a 
control sample with same amount of Eudragit®  E PO was about 6.6. The saturation 
solubilities obtained at pH 4.5 and 6.8 were 0.17 and 2.19 mg/mL respectively. This 
suggests that the increase in solubility was not due to increase in the pH level.  
 
Figure 4.11 Saturation solubility of Ibuprofen Vs Eudragit®  E PO amount 
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Figure 4.12 Saturation solubility of Ibuprofen  
    
 
 
 
 
 
Figure 4.13: Melt Extruded samples (70% Ibuprofen loading) at (a) 30 days (b) 365 
days 
 
Stability 
Melt extruded samples stored at room temperature were observed under polarized light 
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begins to recrystallize from the melt extruded samples with 70% within a week of 
manufacturing.  Figure 4.13 shows microscopic pictures of ibuprofen crystals as seen 
under a polarized light microscope captured at 30 and 365 days. The nucleation 
process started in a week after manufacturing and the crystals were observed to grow in 
size with aging.  
Conclusion 
In this study, solid solutions of ibuprofen and Eudragit® E PO are characterized using 
thermal and microscopic tools. Room temperature miscibility studies provide visible 
evidence of strong affinity between the two components. The strong mutual affinity is an 
additive effect attributed to two components viz. the presence of ionic groups together 
with low Tg of the mixture. Solid solutions prepared by melt extrusion with ibuprofen 
loading 40 and 55% are physically stable at the end of 365 days whereas formulations 
with a drug loading of 70% tend to recrystallize. Stable solid dispersions with high drug 
loading can be achieved by selecting excipients with favorable functional groups. The 
saturation solubility of ibuprofen in acidic media increased up to 12 fold which could be 
attributed to formation of ionic interactions. This is translated in in vitro dissolution 
studies where the ibuprofen release is increased 3 fold as seen in Chapter 3 of this 
document on page 29. This is advantageous for immediate release formulations since 
the dissolution process starts as soon as the drug is orally administered.  
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CHAPTER 5                                                                                                                                  
A QUALITY BY DESIGN (QBD) STUDY ON PREPARATION OF SOLID 
DISPERSIONS USING MELT EXTRUSION PROCESS 
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Introduction 
Over the past two decades Hot Melt Extrusion (HME) has steadily gained interest in the 
pharmaceutical industry owing to the versatile nature of this process(14). Depending on 
the type and combination of excipient selected, HME offers the ability to develop 
formulations with wide applications ranging from immediate release(29), taste 
masking(31), controlled release(30), enteric release(32), pulsatile release as well as 
sterile biological inserts(33). However, solubility enhancement via formation of 
amorphous solid dispersions (SD) remains to be the most widely explored application 
for HME as 40 to 70 % of New Chemical Entities (NCEs) are poorly water soluble(3). 
During SD formation, the drug molecule is entrapped in its most soluble high-energy 
amorphous form by entrapment within the polymeric matrix(71). 
HME offers the ability to combine several individual unit steps such as feeding, melt-
mixing along with numerous downstream processing options like pelletization, granules, 
milled particles, films and custom shapes using injection molding in a continuous 
sequential manner. In spite of the high interest and extensive research only a handful of 
products available on the market are prepared using this technology. This could be due 
to (i) perceived high startup costs (ii) challenges involved in selection of appropriate 
excipients and subsequent prediction of long term stability, as well as (iii) insufficient
understanding of the critical formulation and process parameters and their implications 
on scale up.  
Quality by Design (QbD) is strategic product development approach initiated by the 
Food and Drug Administration (FDA) that considers both, formulation and process 
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related factors that affect the quality attributes of the final product(57). Pharmaceutical 
QbD requires a thorough understanding of the product and the process along with the 
knowledge of the relationship between the Critical Quality Attributes (CQAs) and the 
clinical performance of the product. The effect of individual process parameters on the 
final product’s CQAs is studied with the help of statistical Design of Experiments (DoE) 
through which an operational Design Space (DS) is established. As a result of this, a 
range of variability is defined for each variable under which the CQAs remain within the 
pre-established limits. Thus a controlled DS is generated for the process. Although 
adapting QbD methodology initially could be cumbersome it will eventually mean less 
paperwork and resources when a change needs to be introduced in the manufacturing 
process. It will also reduce overall waste produced during manufacturing as well as 
allow efficient globalization for companies with manufacturing sites across the 
world(58),(59). 
The current QbD methodology involves four major stages: 1. Establishing Quality Target 
Product Profiles (QTPP) and Critical Quality Attributes (CQAs); 2. Risk Assessment; 3. 
DoE-based screening and hence establishing a Design Space (DS); and 4. Control 
Strategy and continuous improvement(57). This pharmaceutical QbD approach has 
been applied to various manufacturing processes such as tablet compression,(59) 
accelerated stability testing,(100) solubility enhancement and dissolution,(101) 
liposomes,(66) spray drying,(62, 63) fluid bed granulation(60) and gel 
manufacturing(69). However this current study focuses on application of QbD 
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framework to a pharmaceutical melt extrusion process, which to date has not been 
reported.  
This present body of work is a case study for developing taste masked granules of 
ibuprofen using Eudragit® E PO using a step-by-step QbD approach. Eudragit® E PO is 
a cationic polymer that is insoluble in water above pH 5.5. This property makes it an 
excellent excipient for taste masking of bitter drugs as it is insoluble at the normal pH of 
human saliva, which ranges from 6.5 to 7.4. Ibuprofen is a non-steroidal anti-
inflammatory agent belonging to BCS (Biological Classification System) Class II (poorly 
soluble and highly permeable)(102). It is an anionic drug with pH dependent solubility 
and readily ionizes at the pH of human saliva (6.5 to 7.4) making it an excellent model 
drug to test the taste masking efficiency of a formulation.  
A thorough risk analysis study using both qualitative and quantitative methods for 
preparation of granules using melt extrusion was performed. Fishbone diagram and 
Failure Mode Effect Analysis (FMEA) were the tools used for qualitative risk analysis. 
For further quantitative investigation a 6 factor 2 level Plackett-Burman screening 
design was formulated to examine the main effects. In order to study potential 
interactions four factors within the Plackett-Burman study were selected for an 
expanded Response Surface Design (RSD). Utilizing these data, a DS for preparation 
of granules using melt extrusion was developed. The steps involved in this QbD study 
are summarized in Figure 5.1. 
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Figure 5.1 QbD steps applied to the melt extrusion process 
Materials 
Ibuprofen was generously donated by Albemarle Corporation (Orangeburg, South 
Carolina). Eudragit® E PO was obtained from Evonik Corporation (Piscataway, NJ). 
PVP 25 was purchased from Sigma-Aldrich (St. Louis, MO). HPLC grade acetonitrile, 
chloroacetic acid, ammonium hydroxide, potassium phosphate and sodium hydroxide 
were purchased from VWR chemical supplies (Radnor, PA).   
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Methods:  
Risk Assessment (RA) 
Risk assessment facilitates strategic short listing and ranking of select significant 
parameters from hundreds of potentially critical parameters. The RA study began with 
devising and enlisting all of the factors that contribute to the quality of the final product 
in the form of a cause and effect or an Ishikawa diagram.(70) Based on the parameters 
highlighted by the Ishikawa diagram, a table for Failure Mode Effect Analysis (FMEA) 
was developed outlining all of the process steps from powder blending to extrusion. A 
team of 5 multidisciplinary experts graded each failure mode on a scale of 1 to 5 with 
regards to the severity (S), occurrence (O) and detectability (D) of that particular event. 
Finally a product of all three values (S*O*D) was computed to yield the Risk Priority 
Number (RPN). 
Experimental Design 
Plackett-Burman design has been shown to be efficient for studying the main effects 
between the critical factors with minimum experimental runs(103). Based on the risk 
assessment results, the shortlisted factors were further analyzed using a Plackett-
Burman screening design consisting of 6 factors studied at two levels along with 2 
center points resulting in a total of 14 extrusion experiments. The high and low level 
values of these factors were based on available literature (31, 104) and prior extrusion 
experience with Eudragit® E PO (data not shown).  
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Based on the results of the Plackett-Burman Design, four factors (Level of Drug: X1, 
Extrusion temperature: X3, Level of processing aid: X6 and level of Eudragit® E PO: 
X7) which had the highest impact on the CQAs, were selected for a custom designed 
Response Surface Design (RSM) with 16 additional runs. The RSM design allowed 
investigation of potential interactions between the independent variables. A list of the 
factors studied (independent variables) along with their levels and the measured 
responses (dependent variables) is presented in Table 5.1. The level of each study 
variable in the experimental design can be seen in Table 5.2. 
Statistical Analysis 
Plackett-Burman design, augmentation of design to a RSM and all statistical 
calculations were performed using JMP® Version 9 (SAS Institute Inc, Cary, NC, USA) 
and Modde 10.0 (Design of Experiment software by Umetrix). Responses were 
analyzed using analysis of variance (ANOVA) and Partial Least Square (PLS). 
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Table 5.1: Experimental domain in Plackett-Burman Design 
 Variable Low Level High Level 
X1 Level of Drug (%w/w) 30 70 
X2 Screw Speed (rpm) 75 150 
X3 Extrusion temperature (°C) 80 140 
X4 Feed Rate (cc/min) 4 6 
X5 Premixing 0 10 
X6 Processing Aid (%w/w) 0 20 
X7 Level of Eudragit® E PO 10 70 
Y1 Torque 
Y2 Glass Transition (°C) 
Y3 Assay (%w/w) 
Y4 Drug Released in 0.5 hr 
Y5 Phase Change 
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Table 5.2: Experimental Design (PB-1 to PB-14: Plackett-Burman design, O-15 to O-30: 
Optimization design) 
Batch 
Ibuprofen 
(%w/w) 
Screw 
Speed 
(rpm) 
Extrusion 
Temperature 
(°C) 
Feed Rate 
(cc/min) 
Mixing 
Processing 
Aid (%w/w) 
Eudragit® 
E PO 
(%w/w) 
PB-1 0.3 75 100 6 0 0.1 0.6 
PB-2 0.3 75 120 4 0 0 0.7 
PB-3 0.3 150 120 4 10 0 0.7 
PB-4 0.3 150 100 4 10 0.1 0.6 
PB-5 0.3 150 100 6 10 0 0.7 
PB-6 0.3 150 120 6 0 0.1 0.6 
PB-7 0.5 75 100 4 10 0.1 0.4 
PB-8 0.5 75 100 6 0 0 0.5 
PB-9 0.5 75 120 6 10 0.1 0.4 
PB-10 0.5 150 100 4 0 0 0.5 
PB-11 0.5 150 120 4 0 0.1 0.4 
PB-12 0.5 150 120 6 10 0 0.5 
PB-13 0.4 112.5 110 5 5 0.05 0.55 
PB14 0.4 112.5 110 5 5 0.05 0.55 
O-15 0.3 112.5 80 5 0 0 0.7 
O-16 0.5 112.5 140 5 0 0 0.5 
O-17 0.3 112.5 80 5 0 0.2 0.5 
O-18 0.7 112.5 110 5 0 0.2 0.1 
O-19 0.3 112.5 140 5 0 0.2 0.5 
O-20 0.7 112.5 140 5 0 0.1 0.2 
Table Continued from previous page 
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O-21 0.7 112.5 80 5 0 0.1 0.2 
O-22 0.7 112.5 110 5 0 0 0.3 
O-23 0.3 112.5 110 4 0 0 0.7 
O-24 0.3 150 110 5 0 0 0.7 
O-25 0.7 112.5 140 5 0 0.2 0.1 
O-26 0.3 112.5 110 5 0 0.2 0.5 
O-27 0.3 112.5 110 6 0 0 0.7 
O-28 0.5 150 110 5 0 0.2 0.3 
O-29 0.7 112.5 80 5 0 0.2 0.1 
O-30 0.3 75 110 5 0 0 0.7 
 
Melt Extrusion 
Dry powder ingredients were sieved through a USP# 35 sieve to remove agglomerates 
and accurately weighed in a plastic bottle. The powder blends were subjected to either 
mixing for 10 min in a Turbula T2F shaker mixer (Glen Mills Inc. Clifton, NJ) or hand 
mixed. The blends were then extruded using a 16 mm co-rotating twin screw extruder 
(Leistritz Corporation, Allendale, NJ) equipped with a bottom feeding assembly and 
fitted with a 4mm round die. The heating zone closest to the feeding zone was 
maintained at 70°C throughout the course of this study whereas heating zones 2, 3 and 
4 were maintained at a temperature stated in the study design. The screw speed (rpm), 
feed rate (cc/min) and the concentration of anti-tacking agent were set up according to 
the study design as shown in Table 5.2. The prepared extrudates were stored in airtight 
containers until further processing. 
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Extrudate Characterization 
Ibuprofen Content 
All melt extruded samples were assayed for ibuprofen content using an Agilent 1100 
series HPLC system (Agilent Technologies Inc, Santa Clara, CA, USA) attached to a 
variable wavelength detector at 254 nm along with a C18 column (Phenomenex Luna 
5µ). A mobile phase consisting of 1% chloroacetic acid buffer solution adjusted to pH 
3.0 with ammonium hydroxide and acetonitrile in the ratio 20:80 was used at a flow rate 
of 0.8 mL/min. All of the standards and assay samples were prepared in methanol. 
Dissolution 
Milled extrudate samples equivalent to 200mg of ibuprofen was filled in a size 00 clear 
gelatin capsule. Dissolution on the filled capsules was performed (n=3) using USP 
apparatus 2 with a Varian VK 750 D dissolution apparatus at 37ºC at a paddle speed of 
50 rpm in biphasic media consisting of pH 1.2 for the initial 60 min. This method was 
followed by utilizing pH 6.8 (simulation of GI tract conditions) until complete ibuprofen 
release was attained. Dissolution samples were filtered and analyzed using the above-
described HPLC method. A control sample, where 200mg of pure drug was placed in a 
size 00 clear capsule was used for comparison. 
Measurement of Tg 
Differential scanning calorimetric analysis was performed on the milled samples using a 
Pyris 6 DSC (PerkinElmer, Waltham, MI). 8–10 mg of the milled extrudate was weighed, 
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crimped in an aluminum pan and subjected to a heat-cool-heat cycle. The first heating 
eliminated the thermal history and moisture whereas the second heating facilitated in 
the determination of Tg. Samples were heated from -30 to 120°C at the rate of 
20°C/min, cooled to -30 °C at 40°C/min and reheated to 120°C at 20°C/min under 
nitrogen purge of 20 mL/min. The Tg was calculated from the resulting thermograms 
using the Pyris 6 software. 
Results and Discussion 
The document Q8 published by the International Conference on Harmonization (ICH) 
illustrates and defines the steps involved in a pharmaceutical QbD process(57). The 
steps followed in this study are outlined in  
The first step for a Quality by Design study is to establish a vision for the end product by 
defining the Quality Target Product Profile (QTPP) for the final product. (57, 58) QTPP 
is a grouping of several chemical, physical, biological, microbiological or esthetic 
attributes of the product that are essential to ensure the quality and performance of the 
drug product. Table 5.3 lists the established QTPP for the melt extrudates manufactured 
in this study, which include the ibuprofen content, in vitro dissolution and physical 
appearance.  These parameters provided as a starting point for establishing the ranges 
of CQAs that serve as a guide throughout the product development phase. The focus in 
this QbD study was to understand the relationship between the experimental 
parameters and formulation composition (independent variables) with the quality 
attributes (responses) that are involved in the melt extrusion process.  
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Table 5.3: Quality Target Product Profile 
Product attribute Target 
Assay > 95% w/w 
Dissolution at pH 1.2 > 60% ibuprofen released in 60 minutes 
Dissolution at pH 6.8 100% of ibuprofen released within 30 minutes 
Physical appearance Clear, non-tacky 
 
Risk Assessment 
From amongst hundreds of factors that potentially affect the melt extrusion product 
development, narrowing down to a few most critical parameters for experimental 
evaluation can be very challenging. A systematic risk assessment study not only 
outlines several factors affecting the process but also prioritizes them based on the 
severity of their impact on the product. In this work, a two-stage risk assessment study 
is conducted to strategically narrow down the most influential parameters. In the first 
step a cause and effect (or Ishikawa diagram) has been utilized to outline a multitude of 
factors contributing from categories such as machine, manpower, materials, methods, 
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measurement and environment(70). The Ishikawa diagram outlining several formulation 
and process parameters affecting the melt extrusion process is illustrated in Figure 5.2. 
All of the resulting factors were then treated as failure modes in a FMEA table, which 
lists the severity, occurrence and predictability for each factor and prioritizes all of the 
risks in the form of a risk priority number (RPN). FMEA is a risk assessment tool that 
focuses on minimizing the potential failures before they occur and assists in developing 
a step by step approach to reduce the future risk of failure by making appropriate 
changes to the process(105). Table 5.4 lists several failure modes with respect to the 
current study along with their effects, causes and controls. These failure modes were 
graded on a scale of 1 to 5 by five experts in this field of study. The final impact of a 
failure mode is decided based on its RPN score calculated as an average score from all 
five evaluations. Drug degradation, melt viscosity, tackiness, flow characteristics and 
drug recrystallization were the failure modes that received the highest RPN scores. 
These are process and formulation variables that can be tested within a specified range. 
These attributes were translated into measurable responses quantified as % Ibuprofen 
content, Tg of the extrudate, in process torque and % ibuprofen released at 30 min. 
Extrudates were examined under a microscope to detect crystallization and qualitative 
phase change. 
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Figure 5.2: Ishikawa diagram for preparation of extruded particles  
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Table 5.4: Failure Mode Effect Analysis for Melt Extrusion Process 
Process 
step 
Failure Mode Failure effects Causes of 
failure mode 
Controls S O D RPN Actions 
Formulation Drug polymer 
ratio 
Compromised 
dissolution 
Supersaturati
on 
Optimization of 
drug-polymer ratio 
5 3.3 1.3 23.3 Optimization 
of drug-
polymer ratio 
Phase 
Change 
Recrystallizatio
n 
Supersaturati
on 
Optimization of 
drug-polymer ratio 
4.6 3 1.6 23 Optimization 
of drug-
polymer ratio 
 Chemical 
Interactions 
Tackniess Lowering of 
Tg 
Lower drug 
loading, revise 
formulation 
4.3 3 1.3 16 Lower drug 
loading, revise 
formulation 
Blending Content 
uniformity 
Uneven 
distribution of 
drug in the 
drug-polymer 
mixture 
Inappropriate 
blending time 
NIR/HPLC 2 3 3.8 28.3 Optimize 
blending 
conditions 
Flow 
Characteritics 
Improper flow, 
feeder jam 
Inadequate 
understanding 
of particle 
properties 
Particle Size, 
Angle of Repose, 
bulk density, tap 
density, Addition of 
glidant 
3.8 3 4.8 53.3 Optimize 
glidant 
concentration 
and feed rate 
Feeding Liquid 
Injection  
Non-uniform 
feeding 
Pump 
malfunction 
Flow rate 
optimization 
5 1.5 3.5 25 Calibrate 
pump, operate 
within 
calibrated 
range 
Feeder Jam Inefficient 
feeder 
Functioning, 
Bridging or 
Arching 
Poor flowing 
material 
Feeder speed and 
conveying screw 
optimization 
3.8 2 3.5 33 Add glidant, 
change feeder 
screws 
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Extrusion Drug 
Degradation 
Drug content 
loss due to 
degradation , 
low assay 
content 
Too high 
temperature, 
Drug/Polymer 
interactions 
lower extrusion 
temperature and 
monitor color 
change 
5 3 4.3 62.5 Reduce 
extrusion 
temperature 
Polymer 
Degradation 
Discoloration/ 
charring, drug 
content loss 
due to 
impurities 
Too high 
temperature, 
Drug/Polymer 
interactions, 
Too high shear 
forces 
lower extrusion 
temperature and 
monitor color 
change 
5 3 2.3 33.8 Reduce 
extrusion 
temperature 
 High melt 
viscosity 
Extruder 
shutdown due 
to overtorgue 
Temperature 
lower than 
necessary, low 
plasticizer 
Monitor torgue 
and viscosity 
values 
4.8 3 4.3 60.5 Increase 
temperature/ 
Lower screw 
speed, 
increase 
plasticizer 
concentration 
Low melt 
viscosity 
Material is very 
liquid, too sticky 
for conveyor 
belt cooling 
High extrusion 
temperature 
Lower extrusion 
temperature   
3.3 2.5 4 28 Decrease 
temperature/ 
Decrease 
plasticizer 
concentration 
Extrudate 
Content 
Uniformity 
Uneven mixing 
of drug in the 
extrusion batch 
Screw 
configuration,  
Length of the 
cylinder 
PAT tools 
(NIR/RAMAN) 
4.3 3 3.3 41.5 Revise screw 
design 
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Crystallization 
of API 
Dissolution 
characteristics, 
visual 
appearance, 
Physical 
Stability, 
Cooling Rate 
High drug load, 
extrusion 
temperature, 
residence time, 
polymer 
characteristics 
PAT tools 
(RAMAN) 
4.3 3.5 3 36.5 Revise 
formulation 
High back 
pressure 
Blocking of the 
die, instrument 
shutdown 
die diameter, 
die 
temperature 
PAT tools: 
(Pressure 
sensor)  
3.3 1.8 4.3 24 Reduce screw 
speed, increase 
die diameter 
Cooling/ 
Conveying 
Uneven 
diameter of 
extrudate 
Uneven 
thickness, a 
strand that is 
not continuous 
Feeder speed, 
conveyor belt 
speed 
Belt speed 1.5 2.8 3.8 14.5 Adjust belt 
speed, keep the 
feeder speed 
uniform 
Milling Particle size 
distribution 
Wide particle 
size distribution 
Blade speed, 
sieve number 
Optimize speed 
and sieve size 
1.5 3.3 3.8 20.5 Optimize speed 
and sieve size 
Storage 
conditions 
Tackiness Granules stick 
to each other 
during storage 
forming lumps 
Low glass 
transition 
temperature of 
the drug 
Store at a lower 
temperature, 
add anti-tacking 
agent 
3.8 3 4.5 52.3 Increase 
concentration of 
antitacking 
agent 
Recrystallizati
on 
Recrystallizatio
n affecting the 
drug dissolution 
Moisture and 
storage 
temperature 
None 5 3.5 3.5 60 Monitor storage 
conditions, 
Store in a 
refrigeration 
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Statistical Design and Analysis 
Table 5.5 shows the response values for all the experiments. The results of the 
screening study showed that the most critical factors were the X1 (ibuprofen content 
%w/w) and X6 (concentration of processing aid %w/w). These factors along with one 
additional factor X3 (extrusion temperature °C) were selected for an optimization study 
using a RSM design. The levels of drug loading and extrusion temperature were 
broadened to increase the resolution of the design in the optimization study as shown in 
Table 5.2. The optimization study design enabled identification of interactions within the 
factors. The results of the RSM design were analyzed using analysis of variance and 
the effects of each factor are discussed separately.  
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Table 5.5: Response values for the extruded batches 
Batch Torque (Gm): Y1 
Glass 
Transition 
(°C):Y2 
Assay 
(%w/w):Y3 
Dissolution at 
30 min (%w/w) 
:Y4 
PB-1 1681.04 22 95.17 71.77 
PB-2 1581.79 16.95 97.54 72.78 
PB-3 1374 14.28 92.32 72.87 
PB-4 1341.03 22.16 92.55 73.76 
PB-5 1066.72 15.46 95.44 72.77 
PB-6 1285.77 22.35 99.03 71.83 
PB-7 875.76 9.08 98.34 70.37 
PB-8 1063.26 7.05 94.03 73.2 
PB-9 1046.5 8.44 98.87 69.98 
PB-10 714 6.38 97.51 69.21 
PB-11 730.56 7.93 94.52 73.18 
PB-12 789.59 7.15 92.23 73.04 
PB-13 1014.86 13.81 97.17 71.82 
PB14 1181.5 12.98 94.5 71.17 
O-15 1437 15.56 98.17 70.88 
O-16 836.01 6.61 96.01 72.13 
O-17 1901.03 18.47 92.46 71.09 
O-18 601.15 -15.65 93.04 26.63 
O-19 1555.93 19.92 96.2 71.3 
O-20 676.39 -2.52 83.46 29.92 
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Table continued from previous page 
O-21 756.08 -12.94 96.77 22.01 
O-22 626.8 -16.56 94.4 19.96 
O-23 819.12 16.37 97.45 70.51 
O-24 1059.11 16.21 96.83 70.21 
O-25 1017.76 -14.96 89.1 21.34 
O-26 2019.1 22.06 96.49 72.35 
O-27 1384.9 17.23 96.68 71.72 
O-28 1134.59 8.16 97.34 72.34 
O-29 977.59 -14.56 97.45 21.56 
O-30 2012.14 15.87 96.17 73.42 
 
Effect of Ibuprofen Loading (X1) 
Unlike traditional solid dosage forms such as tablets and capsules, which mostly involve 
physical mixing and dry processing, melt extrusion is a process where the drug 
molecule is in intimate contact with the excipients and contributes significantly to the 
physico-chemical characteristics of the formulation. For this reason, strategies required 
in formulation development using melt extrusion are unique to a given active ingredient. 
Level of ibuprofen has a significant effect on three of the responses studied namely, 
torque, Tg and dissolution.  
Ibuprofen is a low melting compound with a glass transition temperature below room 
temperature (-45°C).(106) Since ibuprofen exists in its amorphous form within the melt 
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extrudates, the overall Tg of the extruded samples is significantly reduced. The Tg 
lowering effect was found to be a function of ibuprofen concentration in the formulation. 
It has been previously proven that ibuprofen has a plasticizing effect during melt 
processing.(87) As seen in Figure 5.3, ibuprofen content has a negative effect on the in-
process torque indicating that the two variables share an inverse relationship. This 
makes processing at lower temperatures possible thus preventing the possibility of 
adversely affecting the process due to excess torque generation. The Tg lowering effect 
of ibuprofen can be seen in Figure 5.4 where the lowering of Tg with increased 
ibuprofen concentration is evident.  
Eudragit® E PO is a cationic polymer that has been previously shown to form ionic 
interactions with ionic drugs(94). Ibuprofen is an anionic drug that readily forms ionic 
interactions with the cationic polymer Eudragit® E PO thus improving Ibuprofen’s 
solubility in pH 1.2 media. Solubility enhancement also occurs when the API is 
maintained in its amorphous state. There is a significant increase in ibuprofen 
dissolution in comparison to pure ibuprofen in the control sample as seen in Figure 5.6. 
However batches that contain 70% ibuprofen failed the dissolution tests at pH 1.2 due 
to a phase change of ibuprofen from amorphous to crystalline. All samples released 
100% of ibuprofen within 30 minutes of pH change, however the formulations in which 
the drug was present in the amorphous form dissolved faster when pH was changed as 
the drug was molecularly dispersed in the media. In summary, ibuprofen loading was a 
critical parameter having a significant impact on the torque, Tg as well as the dissolution 
behavior. 
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Screw Speed(X2) and Feed Rate(X4) 
Screw speed and feed rate are interdependent parameters in a melt extrusion process 
and both can directly influence the toque generation. When extrusion is carried out at 
higher screw speeds with lower feed rates there is not enough material to fill the screws 
resulting in a starve fed state. In this type of feeding the material overall spends more 
time in the screws resulting in intensive mixing of the components. Flood feeding takes 
place when the feed rate overcompensates the rate at which material is conveyed by 
the screws resulting in excess material in the barrel. A flood fed state also has the risk 
of higher torque values(34). 
In the current study, the screw speed shows a positive effect on the torque values 
whereas the feed rate did not significantly affect the processing at the levels 
investigated in this study design. This can be seen in a Pareto plot for the in process 
torque values (Figure 5.3). It is also interesting to see a relationship pattern between the 
Tg values of the formulation with the in process torque encountered during 
manufacturing.  
Extrusion temperature (X3) 
The extrusion temperatures used in this study design appear to be within the 
degradation limits of the model drug ibuprofen. Although the material can be processed 
as low as 80°C, extrusion temperature of 100°C was found to be most suitable for all of 
the formulations. At temperatures lower than 100°C, the melt exhibits a higher viscosity 
and torque making processing more difficult. Also, it is essential that the drug and the 
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carrier polymer both are in a completely molten state in order to ensure homogenous 
mixing within the extruder barrel. At extrusion temperatures of 140°C, formulations 
containing higher ibuprofen loading became very fluid thus making it difficult to contain. 
Therefore lower extrusion temperatures in the range of 100°C were found to be 
optimum for smooth operation of the extrusion process. Temperature did not have a 
significant impact (p=0.05) on any CQAs studied in this design. However, higher 
extrusion temperatures did have a negative impact on the assay values as seen in 
Figure 5.5.  
Premixing (X5) 
Besides the prior mixing of the physical mixtures, sufficient mixing takes place inside the 
extruder barrel due to the shear from the rotating screws. Out of the four total heating 
zones, mixing elements were positioned between third and fourth zone for this study. 
This ensured that the material is molten when it reaches the mixing zone. Although 
mixing of drug and polymer before feeding to the melt extruder is necessary to avoid 
uneven drug distribution, the method of premixing does not appear to be the most 
critical parameter affecting the content uniformity. The factor for type of mixing (X5) was 
eliminated in the optimization design since based on the screening design it was shown 
to not have direct effect from the type of mixing on the CQAs. 
Processing Aid(X6) 
Due to the low Tg of ibuprofen, batches with a higher ratio of ibuprofen make the melt 
very fluid, sticky and difficult to handle during processing. Two strategies were 
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employed to solve this problem viz. addition of processing aid and extrusion at lower 
temperatures. PVP 25 was tested as an anti-tacking agent and incorporated within the 
study design at 0 and 20%w/w for low and high levels. To test the anti-tacking effect Tg 
was measured for the extruded formulations using a DSC. Although the addition of 
processing aid has a positive effect (p=0.0407) on the Tg of formulations (Figure 5.4), 
this effect does not appear to tackiness of the formulation at higher drug loading 
indicating that PVP 25 did not serve as an efficient anti-tacking agent. Moreover, PVP 
25 failed to dissolve completely in formulations containing lower ibuprofen 
concentrations making the extruded matrix visibly opaque. Physical examination further 
supported the DSC results and it was observed that addition of processing aid was not 
sufficient to reduce the stickiness of the melt extrudates.  
 
Figure 5.3: Sorted parameter estimates showing effect of individual variables on the in 
process torque 
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Figure 5.4: Sorted parameter estimates showing the effect of individual variables on the 
glass transition (Y2) 
 
Figure 5.5: Sorted parameter estimates showing the effect of individual variables on the 
Assay 
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Figure 5.6: Sorted parameter estimates showing the effect of individual variables on 
the% ibuprofen dissolved at 30 min 
 
Figure 5.7: In vitro release from ibuprofen extrudates 
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Development of Design Space 
A design space describes the relationship between the independent (X) variables and 
the dependent (Y) variables graphically(57) and outlines the ranges of input variables 
within which the CQAs remain unaffected, thus maintaining consistent quality. A 
proposed design space for the current study is presented in Figure 5.8. In order to 
achieve and maintain the CQAs within the limits that are defined in the QTPP, the ideal 
drug loading in the range of 35 to 50%w/w and an extrusion temperature ranging 
between 90 to 125°C is recommended.  
In summary, this QbD study assisted in understanding the relationship between the 
experimental factors and their impact on the quality attributes of the melt extrudates with 
minimum experimental runs. It was observed that changes to the formulation such as 
the concentration of the drug and processing aid have the maximum impact on the 
CQAs. Although changes to the process variables like screw speed, feed rate, type of 
mixing and extrusion temperature directly affect the processability, they did not 
significantly affect the CQAs in this study. Experimental limits for formulation and 
process parameters in order for optimum processing have thus been outlined in this 
study. 
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Figure 5.8: Design space for preparation of granules using Melt Extrusion 
Conclusions  
QbD is a step-by-step approach to understand the impact of process variables on the 
quality attributes of the final product and to decide operational experimental limits within 
which the product quality is maintained within the specifications. This study 
demonstrates a qualitative and quantitative risk assessment on factors influencing the 
pharmaceutical melt extrusion process with help of a model drug, ibuprofen. 
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Several formulation and process related factors affecting the quality of melt-extrudates 
were evaluated via a systematic risk assessment study. Out of numerous potentially 
critical parameters, 6 parameters were systematically shortlisted for an experimental 
screening study. Extrusion temperature, screw speed, drug load and level of processing 
aid were identified as critical parameters and their impact on critical quality attributes 
were measured in a Plackett Burman study design.  
This design was further expanded to a RSM design to study potential interactions 
between the three critical variables (X1: drug loading, X3: Extrusion temperature and 
X6: amount of processing aid). Further, the effect of these parameters on the Ibuprofen 
content, Tg, in process torque and in vitro ibuprofen dissolution was analyzed using 
multiple linear regression and analysis of variance. The lowering of glass transition with 
the increase in the Ibuprofen content is evident from the data analysis. The addition of 
PVP 25 as an anti-tacking agent did not significantly increase the Tg of the mixture. The 
prepared extrudates were in line with the QTPP limits. The batches with lower levels of 
ibuprofen exhibited optimal physical attributes whereas the batches with higher drug 
load were slightly tacky due to lowered Tg values.  
A design space plot outlining the ideal operating conditions within which the CQAs 
remain unchanged is presented. An average drug loading temperature of 100°C and 
drug loading levels between 30 and 50%w/w ibuprofen is recommended as optimum 
processing conditions to achieve the QTPP. 
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CHAPTER 6                                                                                                          
EVALUATION OF DRUG RELEASE MECHANISM FROM SOLID DISPERSIONS OF 
KETOCONAZOLE 
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Introduction 
Solid dispersion technology has been gaining interest as a solubility enhancement tool 
for several decades(20). The main mechanism for solubility enhancement via solid 
dispersion formulation is the physical entrapment of drug molecules to maintain the drug 
in its high energy amorphous state. Solid solution can be formed when a drug is 
molecularly dispersed (or solubilized) in the polymer matrix. Depending on the type of 
solid dispersion and the nature of the drug and the carrier materials used, the 
mechanism of the drug release can be different. 
In spite of the intensive research on formulation development of solid dispersions not a 
lot is known about the mechanism of drug release from solid dispersions (39). Several 
theories have been proposed on modeling the drug release from matrix type 
formulations (22, 107). There are generally two types of release mechanisms (carrier 
controlled or drug controlled) observed in carrier based matrix formulations. In carrier 
controlled drug release the dissolution of the drug is independent of the properties of the 
drug molecule. However, at high drug loads there is a shift and the drug dominates the 
rate of dissolution.  
Kollidon® VA 64 is a highly water soluble copolymer prepared from 6 parts of N-
vinylpyrrolidone and 4 parts of Vinyl Acetate. The solubility parameter value for 
Kollidon® VA 64 is 21.1 which means it is likely to be miscible with a broad range of 
drug molecules with solubility parameters between 14.1 to 28.1. Lower hygroscopicity of 
the Kollidon® VA 64 is an advantage in developing dosage forms for water sensitive 
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drug molecules. It is primarily used as a hydrophilic matrix former and helps in 
solubilization of poorly water soluble API. Ketoconazole (KTZ) is a synthetic imidazole 
based antifungal drug primarily used to treat fungal
infections of the skin, scalp and nails. It is a BCS class 2 compound with low aqueous 
solubility and is generally administered via the topical or oral route(108).  
In this study, the drug release mechanism from melt extruded Kollidon® VA 64 and 
ketoconazole matrices is investigated. Physical mixtures of the drug and polymer were 
extruded using a Hot Melt Extruder (ThermoScientific, HAAKE Minilab II) at 140°C and 
60 rpm screw speed. Swelling, erosion, in vitro release (pH 7.4 phosphate buffer and 
0.1N HCl) and mechanical properties of the prepared extrudates were studied. The 
dissolution profiles were fitted using available dissolution models to determine the 
dominant mechanism for drug release. Solid state miscibility value of KTZ in Kollidon® 
VA 64 was measured using a hyper DSC method as described by Gramaglia et al. to 
identify the solubility limits (52).  
 
Figure 6.1: Structure of Kollidon® VA 64 
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Figure 6.2:  Structure of Ketoconazole (Melting point: 146°C) 
Table 6.1: Properties of Kollidon® VA 64 
Parameter Value 
Glass Transition (Tg) 106.2°C 
Degradation Temperature (Tdeg) 290°C 
Extrusion Temperature Range 90- 140°C 
Materials 
Ketoconazole was purchased from Spectrum Chemicals, New Brunswick, NJ, USA. 
Kollidon® VA 64 was generously donated by BASF Corporation, Tarrytown, NY, USA. 
HPLC grade solvents and buffers were purchased from Spectrum Chemicals, New 
Brunswick, NJ 
Methods 
Differential Scanning Calorimetry 
Premixed drug-polymer physical mixtures were weighed (5-7 mg) and hermetically 
sealed into an aluminum sample pan. For determination of solid state solubility, 
previously weight and mixed binary mixtures were subjected to two heating cycles 
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(Perkin Elmer, Diamond DSC). Cycle 1 involved heating at 20°C/min up to 130°C to 
allow the dissolution and saturation of the drug molecules in the polymer matrix. After 
cooling, the sample pan was heated rapidly to 280°C at 400°C/min (cycle 2). The 
sudden heating prevents equilibration and dissolution of crystalline drug into melted 
polymer thus measuring the enthalpy associated with the crystalline phase in the 
sample.  
Melt Extrusion 
Physical mixtures of the drug and polymer at three drug loading (20%, 30% and 40% 
w/w) were prepared by mixing accurately weight drug and polymer in a mortar and 
pestle for 10 min. The mixtures were extruded using a Hot Melt Extruder 
(ThermoScientific, HAAKE Minilab II) at a barrel temperature of 140°C and a screw 
speed of 60 rpm. Material was fed manually using a plunger mechanism. The molten 
drug polymer mixtures were extruded using a slit die and cut into equal sized pieces for 
further evaluation.The prepared extrudates were stored in air tight containers until 
further use. Assay was performed on the melt extruded samples by dissolving the 
extrudate in methanol and analysis using HPLC.  
HPLC Method 
Dissolution and assay samples were analyzed using a chromatographic system which 
consisted of a Waters 600 pump and a dual wavelength Waters 2487 UV detector 
together with a waters Symmetry C18 column, 5 mm particle size (Waters, Milford, MA, 
U.S.A). The mobile phase consisted of 50% acetonitrile and 50% of 25 mM Potassium 
 110 
 
dihydrogen phosphate buffer (pH adjusted to 4.5 with o-phosphoric acid) with a flow rate 
of 1 ml/min. Injection volume of 20 µl was used  for both, the standard and the samples. 
The analysis was performed at 225nm. 
In Vitro Dissolution 
Dissolution behavior of the prepared extrudates was evaluated at pH1.2 and pH 7.4 for 
all prepared extrudates (n=3). The dissolution conditions were set up as indicated in 
Table 6.2. Samples were analyzed using the above mentioned HPLC method.  
Table 6.2: Dissolution parameters 
Parameter Value 
Medium pH 7.4 Phosphate Buffer, 0.1 N HCL 
Apparatus USP Method 5 (Paddle over disc) 
Volume 900 ml 
Sampling Time 5,15,30,45,60,120 min. 
Analytical Method HPLC-UV 
Paddle Speed 50 rpm 
Temperature 37°C 
Swelling and Erosion 
Swelling and Erosion studies were performed in deionized water maintained at 37°C 
with a constant stirring at 100rpm. Samples were pre weighed (W0), placed on a 
backing membrane and then attached to USP apparatus 5 (Figure 6.3) The rate of 
dissolution medium uptake was measured using the equilibrium weight method(109) 
and the erosion studies were performed based on the loss of dry weight method. A 
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fresh sample was used for each time point. The films were subjected to the media with 
rotating paddles for the specified period of time then removed and weighed (W1) after 
blotting excess solvent for swelling measurements. For measurement of erosion, the 
samples were further dried in oven (60°C) until a constant weight was obtained.  
The percent swelling and erosion were calculated using the following formula 
%!!"#$$%&' = !"" ∗ ! !!!! !!! !          (6.1) %!!"#$%#& = !"" ∗ !!!! !!! !!         (6.2) 
Where, 
W0 = Original weight of patch,  
W1=Weight of patch after media uptake 
W2 = Weight of desiccated patch (stored for 24hrs at 60°C) 
 
Figure 6.3: Schematic of USP Apparatus 5 used for swelling and erosion studies 
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Puncture Test 
Puncture test was performed using a Texture Analyzer (Texture Technologies TA XT 
Plus with a test speed of 2mm/sec attached with a TA-8 probe. The compression force 
required for breaking a piece of extrudate was measured and the puncture strength was 
calculated based on the following formula 
!"#$%"&'!!"#$%&"' = ! !!        (6.3) 
Where,  
F=Load required to puncture the film 
A=Cross Sectional Area  
Results and Discussion 
Dissolution of Melt Extrudates 
Melt extrudates of Kollidon® VA 64 with 20%, 30% and 40% ketoconazole were 
evaluated for drug content (Figure 6.4). All prepared extrudates have more that 95%w/w 
of ketoconazole and have a clear glassy appearance. The drug dissolution from solid 
dispersions may be described based on the Noyce-Whitney equation (Page 4)(22). The 
rate of dissolution of drug is controlled by either the solubility of the drug or the solubility 
of carrier in the testing media.  
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Figure 6.4: Post extrusion KTZ content 
The pH dependent solubility of KTZ has been documented in the literature and it has 
been reported that KTZ rapidly precipitated out of the solution as the pH of the medium 
exceeded 5.5 (110). In this study, it was observed that the rate of dissolution of KTZ is 
faster at pH 1.2 where <80%w/w drug is released within in the first 15 minutes. The drug 
ratio has a direct relationship with the dissolution rate where the formulations containing 
40% KTZ loading appears to show the fastest drug release. The drug release slowed in 
pH 7.4 with almost all the drug released in 45 minutes and the effect of drug ratio 
appears to have reversed when compared to acidic pH. 
 
0 
20 
40 
60 
80 
100 
20% KTZ 30% KTZ 40% KTZ 
%
 K
TZ
 c
on
te
nt
 
Hot Melt Extrudates of Kollidon VA 64 
 114 
 
 
Figure 6.5: In vitro dissolution of KTZ from HME Kollidon® VA 64 matrices in pH 1.2 
 
Figure 6.6: In vitro dissolution of KTZ from HME Kollidon® VA 64 matrices in pH 7.4 
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Swelling and erosion studies were performed to determine the dominant mechanism of 
drug release from the KTZ solid dispersions. According to Noyce-Whitney theory, the 
composition of the diffusion layer governs the mechanism of drug release. Since 
Kollidon® VA 64 is a highly water soluble polymer there appears to be very minimal 
swelling as seen in Figure 6.7. In fact, the loss in weight of the matrix is evident even 
during the swelling studies. Further, as seen in Figure 6.8, almost 80% of the matrix is 
dissolved (or eroded) in the first 10 minutes. The high erosion rate can be attributed to 
the fact that the primary release mechanism is carrier based and the high water 
solubility of the carrier polymer is responsible for fast matrix erosion.  
 
Figure 6.7: Swelling behavior of Ketoconazole melt extrudates 
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Figure 6.8: Swelling behavior of Ketoconazole melt extrudates 
Table 6.3: Dissolution data modeling 
Formulation First Order 
Korsemeyer-
Peppas 
20% KTZ, pH 7.4 0.9865 0.8662   
30% KTZ, pH 7.4 0.9966 0.8916  
40% KTZ, pH 7.4 0.9687 0.8960  
20% KTZ, 0.1NHCl 0.9406 0.9365 
30% KTZ, 0.1NHCl 0.8619 0.9272 
40% KTZ, 0.1N HCl 0.9749 0.8733 
Drug release from solid dispersions may overall be classified in two mechanisms. The 
immediate release formulations generally follow an erosion based release pattern and 
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controlled release formulations exhibit predominantly diffusion based release from 
swelling of the carrier polymer. Since Higuchi first published the modeling of sustained 
drug release, several mathematical models are available to model dissolution data(111). 
In the current study, dissolution data was fitted into two mathematical models: First 
order and Korsemeyer-Peppas. As seen in Table 6.3, the first order model appears to 
be a better fit for the KTZ solid dispersions. 
Puncture Test 
The physical strength of the extrudate can have an impact on the drug release 
characteristics where slower drug release may be observed from tough, highly compact 
matrices. In the current study the mechanical strength of the solid dispersion matrix was 
evaluated using puncture test. A sample graph of the puncture test measurement is 
shown in Figure 6.9. The drug loading appears to have a direct effect on the mechanical 
strength of the prepared matrix. The force required to puncture a slab of prepared solid 
dispersions increased as the drug loading increased. The erosion pattern of these 
matrices also follows a similar trend as seen in Figure 6.8.  
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Figure 6.9: Puncture Test Graph (Force (Kg) Vs Time (Sec) 
Table 6.4: Puncture Strength of Ketoconazole melt extrudates 
Sample Name Puncture Strength 
(dyne/cm2) (X 108) 
Pure Kollidon® VA 64  0.74 +0.19 
20% KTZ 1.07 +0.46 
30% KTZ 1.05 +0.53 
40% KTZ 1.1 +0.11 
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Solubility Determination using Rapid DSC 
Enthalpy is a function of crystallinity in a system and is directly proportional to the 
amount of crystalline drug present. A rapid DSC measures the enthalpy associated with 
the crystalline phase present in the sample without allowing any time for sample 
equilibration. This prevents additional drug being solubilized in the molten polymer 
during the DSC analysis. In this study, the highest concentration of drug that yields a 
zero enthalpy value is determined(112). The predicted solid state solubility of KTZ in 
Kollidon® VA 64 is 9.42%w/w as calculated by the Hyper-DSC method (Figure 6.10). No 
melting event was observed for extrudate samples well above this limit. This can be 
attributed to the limitations of Hyper DSC as a method for solid state solubility 
determination. Although this method is fast and easy the solubility value may be 
underestimated. Another point to note is that the due to high molecular weight of the 
polymer chains the molecular movements in solid dispersion are very slow and can take 
days to achieve equilibrium.  
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Figure 6.10: Rapid-DSC thermograms (heating cycle 2) and respective enthalpy values 
of KTZ-Kollidon® VA 64 systems 
 
Figure 6.11: Linearity plot of Enthalpy Vs Concentration of for Kollidon® VA 64-
Ketoconazole systems 
 121 
 
Conclusions 
Whenever new formulations are being developed it is important to understand how they 
will behave in vivo. Understanding the type of release mechanism will facilitate in vivo 
prediction based on in vitro results. Melt extruded solid dispersions were successfully 
prepared and evaluated. Post extrusion drug content was more than 95% in all three 
formulations tested. Release of ibuprofen from the solid dispersions prepared with 
Kollidon® VA 64 was dependent on the physical state of the drug, solubility of polymer 
and the ratio of drug in the matrix. Increase in drug loading increased the physical 
strength of the extrudates. Swelling and Erosion studies revealed that matrix erosion is 
the dominant mechanism of matrix disintegration. Thus, the primary mechanism of drug 
release is postulated to be carrier controlled and the enhanced dissolution is attributed 
to the high water solubility of the carrier polymer. The dissolution data was fitted into 
available mathematical models. 
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Residence Time Determination 
Melt extrusion is a thermal process in which the components are subjected to high 
amount of heat, pressure and agitation. It is important that the material in contact with 
these extreme conditions for the least amount of time possible to minimize the 
possibility of degradation. In order to achieve this, adequate knowledge about the 
process parameters is necessary. Residence time analysis enables the investigators to 
determine the exact amount of time the API will be exposed to the extreme conditions 
inside the extruder. Using this information, the investigator can make the necessary 
modifications to the process to achieve minimum degradation.  
Residence time analysis is also beneficial when running small sized batches one after 
the other which is often necessary when handling small amount of API. In such 
situations, the investigator will know exactly at which point the sample collection should 
begin. This residence time analysis served as a guide for sample collection for melt 
extrusion batches prepared in this study. 
Method 
Residence time measurement studies on the Leistritz Nano 16 twin screw extruder were 
performed to determine the time spent by the drug inside the extruder barrel. Residence 
time measurements were performed using demo system of Ibuprofen and Eudragit® E 
PO at a screw speed of 150 rpm. Talc was fed in the beginning of the batch and acted 
as a marker. The time required for the first trace of talc to appear was noted. Samples 
collected at 2 minute intervals were analyzed for ibuprofen content by UV spectroscopy. 
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20-40 mg sample was dissolved in 10 ml of methanol and the resulting solution was 
analyzed at 266nm.  
Results 
Figure 8.1 shows the distribution of ibuprofen as a function of time at which it exits the 
die. The results of this study indicate that it requires 8 minutes for the drug 
concentration to reach 80%. Analysis of the placebo batch that was run following the 
drug loaded batch revealed that the placebo batch continues to carry the drug 
molecules trapped inside the extruder barrel. It takes three individual placebo batches in 
order to bring the drug concentration below the detection limits. 
 
Figure 8.1: Drug distribution during melt extrusion (n=3) 
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Conclusion 
Residence time of the contents inside he extruder was determined and the distribution 
of the drug inside the extruder barrel was analyzed. Such measurements provide 
valuable information about the movement of material inside the extruder. This 
information can also help reduce drug loss from the processing.  
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